Combination of anti-PD-1 antibodies and bispecific anti-CD20 / anti-CD3 antibodies for treatment of cancer
Through the combination therapy of PD-1 inhibitor and bispecific anti-CD20/anti-CD3 antibodies, the existing B-cell cancer treatment methods are solved in poor efficacy and drug resistance in patients with invasive lymphoma, and the tumor growth delay is achieved and Recurrence prevention improves treatment effectiveness and safety.
Patent Information
- Application Number
- CN202411255248.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2015-12-22
- Filing Date
- 2016-12-21
- Publication Date
- 2024-11-22
AI Technical Summary
The existing B-cell cancer treatment methods have limited effect on patients with aggressive lymphoma, and common anti-CD20 therapies are resistant to some patients, resulting in recurrence and adverse side effects, and cannot effectively prevent tumor recurrence.
Using a combination therapy of PD-1 inhibitors and bispecific anti-CD20/anti-CD3 antibodies, the immune attack on tumor cells is enhanced by blocking the PD-1 signaling pathway and bridging CD20-expressing cells.
Delay tumor growth, prevent tumor recurrence, increase patient survival duration, reduce the frequency of chemotherapy, and reduce side effects, significantly improve the therapeutic effect on B-cell cancer.
Smart Images

Figure BDA0005033842960000331 
Figure BDA0005033842960000341 
Figure BDA0005033842960000351
Abstract
Description
[0001] This application is a divisional application of Chinese application No. 201680075172.2, whose application date is December 21, 2016 and whose invention name is “Anti-PD-1 antibody and bispecific anti-CD20 / anti-CD3 antibody combination for treating cancer”.
[0002] This application was filed on December 21, 2016 as a PCT international patent application and claims priority to U.S. Provisional Patent Application No. 62 / 270,749 filed on December 22, 2015, the disclosure of which is hereby incorporated by reference in its entirety.
[0003] Sequence Listing
[0004] This application includes a sequence listing in electronic format as a text file entitled "Sequence Listing", which was created on December 21, 2016 and is 13.7 kilobytes (KB) in size. The contents of the text file "Sequence Listing" are incorporated herein by reference. Technical Field
[0005] The present invention relates to a method for treating cancer, comprising administering to an individual in need thereof a therapeutically effective amount of an antibody that specifically binds to the programmed death 1 (PD-1) receptor in combination with a bispecific antibody that binds to CD20 and CD3. Background Art
[0006] B cell cancer is a group of heterogeneous cancers of white blood cells called B lymphocytes and includes leukemias (located in the blood) and lymphomas (located in the lymph nodes). B cell lymphomas include, but are not limited to, non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma (HL). Lymphomas are divided into indolent (slowly forming) or aggressive lymphomas (aggressivelymphomas). Common indolent lymphomas are follicular lymphomas, while the most common aggressive lymphomas are diffuse large B cell lymphomas. B cell leukemias include, but are not limited to, acute lymphocytic leukemia, hairy cell leukemia, and B cell chronic lymphocytic leukemia.
[0007] Most B cell cancers express CD20 on the cell surface of mature B cells. Methods for treating cancer by targeting CD20 are known in the art. For example, the chimeric anti-CD20 monoclonal antibody rituximab has been used or suggested for the treatment of cancers such as NHL, chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), or used as a monotherapy, but more often combined with chemotherapy. Although the anti-CD20 tumor targeting strategy has shown great promise in clinical settings, not all patients respond to anti-CD20 therapy, and it has been confirmed that for reasons that are not yet fully understood (but generally do not include loss of CD20 expression), some patients develop resistance to anti-CD20 therapy or show incomplete remission (e.g., peripheral B cells are partially exhausted). Some patients relapse with a more aggressive phenotype or chemotherapy-resistant disease. Many aggressive lymphoma patients have a poor prognosis and have less than 50% chance of recurrence-free survival. The prognosis of patients who relapse or resist treatment is still bleak, with a median survival of 2 to 8 months after salvage therapy. In addition, high-dose chemotherapy causes serious adverse side effects. Therefore, there is a high unmet need for therapies that are effective for patients with B-cell cancers, prevent relapse, and have fewer side effects.
[0008] Programmed death-1 (PD-1) receptor signaling in the tumor microenvironment plays a key role in allowing tumor cells to escape immune surveillance by the host immune system. Blocking the PD-1 signaling pathway has demonstrated clinical activity in patients with multiple types of tumors, and antibody therapeutics that block PD-1 (e.g., nivolumab and pembrolizumab) have been approved for the treatment of metastatic melanoma and metastatic squamous non-small cell lung cancer. Recent data have demonstrated the clinical activity of blocking PD-1 in patients with invasive NHL and Hodgkin's lymphoma (Lesokhin et al., 2014, Abstract 291, 56th ASH Annual Meeting and Exposition, San Francisco, CA; Ansell et al., 2015, N. Engl. J. Med. 372 (4): 311-9).
[0009] CD3 is a homodimeric or heterodimeric antigen expressed on T cells that associates with the T cell receptor complex (TCR) and is required for activation of T cells. Antibodies against CD3 have been shown to cluster CD3 on T cells, thereby causing T cell activation in a manner similar to the engagement of TCR with peptide-loaded MHC molecules. Bispecific monoclonal antibodies designed to target CD20 and CD3 bridge CD20-expressing cells with cytotoxic T cells, resulting in CD20-directed polyclonal T cell killing.
[0010] Given the high unmet need for effective therapies against B-cell malignancies, as shown herein, it is possible to combine treatment with drugs that enhance T-cell function (e.g., PD-1 inhibitors such as anti-PD-1 antibodies) with drugs directed against the target antigen (bispecific anti-CD20 / anti-CD3 antibodies). Brief description of the invention
[0012] According to certain embodiments, the present invention provides a method of treating cancer in an individual, alleviating at least one symptom or indication thereof, or inhibiting its growth. The method according to this aspect of the invention comprises administering to an individual in need thereof a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds to programmed death 1 (PD-1), in combination with a therapeutically effective amount of a bispecific antibody that specifically binds to CD20 and CD3.
[0013] In certain embodiments of the present invention, methods for treating cancer in an individual, alleviating at least one symptom or indication thereof, or inhibiting its growth are provided. In certain embodiments of the present invention, methods for delaying tumor growth or preventing tumor recurrence are provided. According to this aspect of the present invention, these methods include sequentially administering to the desired individual one or more doses of a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds to PD-1, in combination with one or more doses of a therapeutically effective amount of a bispecific antibody that specifically binds to CD20 and CD3.
[0014] In certain embodiments, the cancer or tumor is a heme cell tumor or a malignant tumor. In certain embodiments, the cancer or tumor is a B cell tumor. In certain embodiments, the B cell tumor is selected from Hodgkin's lymphoma, non-Hodgkin's lymphoma, follicular lymphoma, small lymphocytic lymphoma, lymphoplasmacytoid lymphoma, marginal zone lymphoma, mantle cell lymphoma, diffuse large B cell lymphoma, B cell lymphoma, lymphomatoid granuloma, Burkitt's lymphoma, acute lymphocytic leukemia, hairy cell leukemia and B cell chronic lymphocytic leukemia.
[0015] In certain embodiments, each dose of anti-PD-1 antibody is 0.1-20 mg / kg of individual body weight. In certain embodiments, each dose of anti-PD-1 antibody is 0.3 mg / kg, 1 mg / kg, or 3 mg / kg of individual body weight. In certain embodiments, each dose of anti-PD-1 antibody is 50-600 mg.
[0016] In certain embodiments, each dose of a bispecific antibody against CD20 and CD3 is 0.1-10 mg / kg of individual body weight. In certain embodiments, each dose of a bispecific antibody is 10-8000 micrograms.
[0017] In certain embodiments, each dose of anti-PD-1 antibody is 0.3 mg / kg of individual body weight, 1 mg / kg of individual body weight, 3 mg / kg of individual body weight, or 10 mg / kg of individual body weight, and each dose of bispecific antibody is 10-3000 micrograms. In certain embodiments, each dose of anti-PD-1 antibody is 1, 3, or 10 mg / kg of individual body weight and each dose of bispecific antibody is 100, 300, 1000, or 3000 micrograms. In certain embodiments, each dose of anti-PD-1 antibody is 50-300 mg and each dose of bispecific antibody is 100, 300, 1000, or 3000 micrograms.
[0018] In certain embodiments, the methods of the invention comprise administering a therapeutically effective amount of an anti-PD-1 antibody prior to, concurrently with, or after a bispecific antibody that specifically binds to CD20 and CD3. In one embodiment, the methods of the invention comprise administering an anti-PD-1 antibody prior to a bispecific anti-CD20 / anti-CD3 antibody.
[0019] In certain embodiments, the methods of the present invention include administering 0-50 therapeutic doses of each of an anti-PD-1 antibody and a bispecific antibody for CD20 and CD3, wherein each dose is administered 0.5-12 weeks after the immediately preceding dose. In certain embodiments, each dose of the anti-PD-1 antibody is administered once a week, once every two weeks, or once every four weeks, and each dose of the bispecific antibody is administered once a week, once every two weeks, or once every four weeks. In one embodiment, each dose of the anti-PD-1 antibody is administered once every two weeks and each dose of the bispecific antibody is administered once a week.
[0020] In certain embodiments, each dose of the bispecific antibody (as divided doses) is administered in more than one portion, for example, as 2 or more portions over the dosing period.
[0021] In certain embodiments, the anti-PD-1 antibodies and bispecific antibodies are administered in combination with a third therapeutic agent or a third therapy.
[0022] According to certain embodiments, the anti-PD-1 antibody or antigen binding protein comprises a heavy chain complementarity determining region (HCDR) of a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 1 and a light chain CDR of a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 2. One such type of antigen binding protein that can be used in the methods of the invention is an anti-PD-1 antibody such as REGN2810.
[0023] According to certain embodiments, a bispecific antibody that binds to CD20 and CD3 comprises: (i) a first antigen binding arm comprising the heavy chain CDRs (A-HCDR1, A-HCDR1, and A-HCDR3) of a HCVR (A-HCVR) of SEQ ID NO: 11 and the light chain CDRs (LCDR1, LCDR2, and LCDR3) of a LCVR of SEQ ID NO: 12; and (ii) a second antigen binding arm comprising the heavy chain CDRs (B-HCDR1, B-HCDR2, and B-HCDR3) of a HCVR (B-HCVR) of SEQ ID NO: 13 and the light chain CDRs (LCDR1, LCDR2, and LCDR3) of a LCVR of SEQ ID NO: 12.
[0024] In certain embodiments, the present invention provides the use of an anti-PD-1 antibody or an antigen-binding fragment thereof, alone or in combination with a bispecific antibody for CD20 and CD3, in the preparation of a medicament for treating or inhibiting cancer growth in an individual (including a human). In certain embodiments, the cancer is a B cell cancer. In one embodiment, the cancer is a non-Hodgkin's lymphoma. In one embodiment, the cancer is a Hodgkin's lymphoma. In one embodiment, the cancer is an acute lymphoblastic leukemia.
[0025] Other embodiments of the present invention will become apparent upon reading the following detailed description. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] Figure 1 Summarized are the in vivo efficacy results of anti-mouse PD-1 antibodies alone and in combination with bispecific anti-CD20 / anti-CD3 antibodies against established B16_CD20+ tumors (described in Example 1 herein).
[0028] Figure 2 Shown are mice randomized into cohorts based on tumor size (as described in Example 2 herein).
[0029] Figure 3 Summarized are the in vivo efficacy results of anti-mouse PD-1 antibodies alone and in combination with bispecific anti-CD20 / anti-CD3 antibodies against established B16_CD20+ tumors (described in Example 2 herein).
[0030] Figure 4 A schematic diagram of treatment groups and dose cohorts for lymphoma (B-cell non-Hodgkin lymphoma and Hodgkin lymphoma) patients (described in Example 3 herein) is shown.
[0031] Figure 5 Schematic diagram showing treatment groups and dose cohorts for acute lymphoblastic leukemia patients (described in Example 3 herein).
[0032] Figure 6 is a flow chart of the study of a single-agent anti-PD-1 antibody (REGN2810) treatment regimen for patients with lymphoma (B-cell non-Hodgkin lymphoma and Hodgkin lymphoma) (described in Example 3 herein).
[0033] Figure 7 Flowchart of a study of a single-agent anti-CD20 / anti-CD3 bispecific antibody (bsAb1) treatment regimen for patients with acute lymphoblastic leukemia (described in Example 3 herein).
[0034] Figure 8 Flow chart of the study of bsAb1+REGN2810 combination therapy for patients with B-cell non-Hodgkin's lymphoma (described in Example 3 herein).
[0035] Fig. 9 Flow chart of the study of bsAb1+REGN2810 combination therapy for patients with acute lymphoblastic leukemia (described in Example 3 herein). DETAILED DESCRIPTION OF THE INVENTION
[0037] Before describing the present invention, it should be understood that the present invention is not limited to the specific methods and experimental conditions described, because such methods and conditions can be changed. It should also be understood that the terminology used herein is intended only to describe specific embodiments, and is not intended to be restrictive, because the scope of the present invention will be limited only by the appended claims.
[0038] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention belongs. As used herein, the term "about" when used in reference to a specific recited value means that the value may vary by no more than 1% from the recited value. For example, as used herein, the expression "about 100" includes all values between 99 and 101 and between (e.g., 99.1, 99.2, 99.3, 99.4, etc.).
[0039] Although any methods and materials similar or equivalent to those described herein can be used in the practice of the present invention, the preferred methods and materials are described herein. All publications mentioned herein are incorporated by reference in their entirety.
[0040] Methods of treating or inhibiting the growth of B-cell cancer
[0041] The present invention includes methods for treating cancer in an individual, alleviating or reducing the severity of at least one symptom or indication thereof, or inhibiting its growth. The method according to this aspect of the invention comprises administering to the desired individual a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds to the PD-1 receptor, and a therapeutically effective amount of a bispecific antibody against CD20 and CD3. As used herein, the terms "treatment", "treatment", etc., mean to alleviate symptoms, eliminate the causal relationship of symptoms on a transient or permanent basis; mean to delay or inhibit tumor growth; mean to reduce tumor cell load or tumor load; mean to promote tumor regression; mean to cause tumor shrinkage, necrosis and / or disappearance; mean to prevent tumor recurrence, and / or mean to increase the duration of survival of an individual.
[0042] As used herein, the expression "required individual" means a person or non-human mammal who shows one or more symptoms or indications of cancer and / or has been diagnosed with cancer (including B-cell cancer) and needs to be treated for the former. In many embodiments, the term "individual" can be used interchangeably with the term "patient". For example, a human individual can be diagnosed with a primary or metastatic tumor and / or have one or more symptoms or indications, including but not limited to enlarged lymph nodes, abdominal distension, chest pain / stiffness, unexplained weight loss, fever, night sweats, persistent fatigue, loss of appetite, enlarged spleen, itching. This expression includes individuals with primary or existing B-cell tumors. In a specific embodiment, the expression includes a human individual who is receiving and in need of treatment for a B-cell malignancy (e.g., Hodgkin's lymphoma, non-Hodgkin's lymphoma, follicular lymphoma, small lymphocytic lymphoma, lymphoplasmacytoid lymphoma, marginal zone lymphoma, mantle cell lymphoma, diffuse large B-cell lymphoma, B-cell lymphoma, lymphomatoid granuloma, Burkitt's lymphoma, acute lymphocytic leukemia, hairy cell leukemia, and B-cell chronic lymphocytic leukemia). In yet another embodiment, the expression includes a person having a B-cell cancer pathological subtype as listed in Tables 3-5 herein. In other specific embodiments, the expression includes CD20+ tumor individuals (e.g., tumors expressing CD20, as determined by flow cytometry on ≥20% leukemic lymphoblastoid cells). In certain embodiments, the expression "individual in need" includes patients with B-cell cancers that are resistant or resistive to or inadequately controlled by previous treatments (e.g., conventional anticancer drug treatments). For example, the expression includes individuals who have been treated with CD20 inhibitors (e.g., rituximab), chemotherapy, or immunomodulatory drugs such as blockers CTLA, IBB, LAG3, or OX-40. The expression also includes patients with the following B-cell malignancies, where, for example, conventional anticancer therapy is not recommended for the B-cell malignancies due to toxic side effects. For example, the expression includes such patients, the patients have received one or more cycles of chemotherapy, accompanied by toxic side effects. In certain embodiments, the expression "required individuals" includes patients with the following B-cell malignancies, the B-cell malignancies have been treated, but have subsequently relapsed or metastasized. For example, such B-cell malignancies are treated with the methods of the present invention, and the patients may have been treated with one or more anticancer drugs, resulting in tumor regression; however, they have subsequently relapsed with cancers that are resistant to one or more anticancer drugs (e.g., chemotherapy-resistant cancers).
[0043] The expression "individual in need thereof" also includes individuals at risk for developing B-cell cancer, for example, individuals with a family history of lymphoma, individuals with a past history of Epstein-Barr infection (such as infectious mononucleosis), or individuals whose immune systems are compromised due to HIV infection or due to immunosuppressive drugs.
[0044] In certain embodiments, the methods of the invention can be used to treat patients who exhibit elevated levels of one or more cancer-associated biomarkers [e.g., programmed death ligand 1 (PD-L1), CD20, beta-2-microglobulin, lactate dehydrogenase, BCR-ABL fusion gene, ALK gene rearrangement]. For example, the methods of the invention comprise administering a therapeutically effective amount of an anti-PD-1 antibody in combination with a bispecific anti-CD20 / anti-CD3 antibody to a patient with elevated levels of PD-L1 and / or CD20.
[0045] In certain embodiments, the methods of the present invention are used in individuals with B cell cancer. The terms "tumor", "cancer" and "malignant tumor" are used interchangeably herein. As used herein, the term "B cell cancer" refers to a tumor of a white blood cell called a B-lymphocyte and includes leukemia (located in the blood) and lymphoma (located in the lymph nodes). The present invention includes methods for treating leukemia and lymphoma. In certain embodiments, B cell cancer includes but is not limited to Hodgkin's lymphoma, non-Hodgkin's lymphoma, follicular lymphoma, small lymphocytic lymphoma, lymphoplasmacytoid lymphoma, marginal zone lymphoma, mantle cell lymphoma, diffuse large B cell lymphoma, B cell lymphoma, lymphomatoid granuloma, Burkitt's lymphoma, acute lymphocytic leukemia, hairy cell leukemia and B cell chronic lymphocytic leukemia and the pathological subtypes listed in Tables 3-5 herein. B cell lymphomas are generally divided into low grade and high grade, which generally correspond to indolent (slow growing) lymphomas and aggressive lymphomas, respectively. The present invention includes methods of treating both indolent and aggressive lymphomas.
[0046] According to certain embodiments, the present invention includes methods for treating tumors, or delaying or inhibiting tumor growth. In certain embodiments, the present invention includes methods for promoting tumor regression. In certain embodiments, the present invention includes methods for reducing tumor cell load or reducing tumor load. In certain embodiments, the present invention includes methods for preventing tumor recurrence. According to this aspect of the present invention, it includes sequentially administering to the desired individual a therapeutically effective amount of an anti-PD-1 antibody in combination with a bispecific anti-CD20 / anti-CD3 antibody, wherein each antibody is administered to the individual at multiple doses (e.g., as part of a specific therapeutic dosing regimen). For example, a therapeutic dosing regimen may include administering one or more doses of anti-PD-1 antibodies to an individual at a frequency of about once a day, once every two days, once every three days, once every four days, once every five days, once every six days, once a week, once every two weeks, once every three weeks, once every four weeks, once a month, once every two months, once every three months, once every four months, or less frequently. In certain embodiments, one or more doses of anti-PD-1 antibody are administered in combination with one or more doses of a therapeutically effective amount of a bispecific anti-CD20 / anti-CD3 antibody, wherein one or more doses of bispecific antibody are administered to an individual at a frequency or lower frequency of about once a day, once every two days, once every three days, once every four days, once every five days, once every six days, once a week, once every two weeks, once every three weeks, once every four weeks, once a month, once every two months, once every three months, once every four months. In certain embodiments, each dose of anti-CD20 / anti-CD3 antibody (as divided doses) is administered in more than 1 portion, for example, in 2-5 portions (divided doses) within a given dosing phase. The anti-CD20 / anti-CD3 bispecific antibody can be administered in divided doses to reduce or eliminate the "surge" of cytokines induced in response to the administration of antibodies. Cytokine spikes refer to clinical symptoms of cytokine release syndrome ("cytokine storm") and infusion-related reactions seen in patients administering anti-CD20 antibodies. In certain embodiments, the methods of the present invention comprise administering to a desired individual one or more doses of an anti-PD-1 antibody in combination with one or more doses of a bispecific anti-CD20 / anti-CD3 antibody, wherein the dose of the bispecific antibody is administered as divided doses or in more than one portion, e.g., as 2 portions, as 3 portions, as 4 portions, or as 5 portions within a given administration period. In certain embodiments, the dose of the bispecific antibody is divided into 2 or more portions, wherein each portion contains an amount of antibody equal to that of the other portions. For example, a dose of an anti-CD20 / anti-CD3 antibody containing 1000 micrograms can be administered once a week, wherein the dose is administered in 2 portions within that week, each portion containing 500 micrograms.In certain embodiments, the dose of the bispecific antibody is administered in 2 or more portions, wherein each portion contains an unequal amount (e.g., more or less than the first portion) of the antibody. For example, a dose of an anti-CD20 / anti-CD3 antibody containing 1000 micrograms can be administered once a week, wherein the dose is administered in 2 portions during the week, wherein the first portion contains 700 micrograms and the second portion contains 300 micrograms. As another example, a dose of an anti-CD20 / anti-CD3 antibody containing 1000 micrograms can be administered in 2 weeks, wherein the dose is administered in 3 portions over a 2-week period, wherein the first portion contains 400 micrograms, the second portion contains 300 micrograms and the third portion contains 300 micrograms.
[0047] In certain embodiments, the present invention includes methods of inhibiting, delaying or stopping tumor metastasis or tumor infiltration into peripheral organs. According to this aspect, these methods include administering a therapeutically effective amount of an anti-PD-1 antibody to an individual in need thereof. In certain embodiments, the anti-PD-1 antibody is administered in combination with a bispecific anti-CD20 / anti-CD3 antibody.
[0048] In a specific embodiment, the present invention provides a method for increasing anti-tumor efficacy or increasing tumor inhibition. According to this aspect of the invention, these methods include administering a therapeutically effective amount of an anti-PD-1 antibody to a B-cell cancer individual before administering a therapeutically effective amount of a bispecific anti-CD20 / anti-CD3 antibody, wherein the anti-PD-1 antibody can be administered about 1 day, more than 1 day, more than 2 days, more than 3 days, more than 4 days, more than 5 days, more than 6 days, more than 7 days, or more than 8 days before the bispecific antibody. In certain embodiments, a method for increasing tumor inhibition, for example, by about 20%, more than 20%, more than 30%, more than 40%, more than 50%, more than 60%, more than 70%, or more than 80%, is provided compared to an individual to whom the bispecific antibody is administered before the anti-PD-1 antibody.
[0049] In certain embodiments, the methods of the present invention include administering a therapeutically effective amount of an anti-PD-1 antibody to a B cell cancer individual. In specific embodiments, the B cell cancer is Hodgkin's lymphoma or non-Hodgkin's lymphoma. In other embodiments, the B cell cancer is inert or aggressive. In certain embodiments, the individual does not respond to previous treatment or has relapsed after previous treatment. In certain embodiments, the methods of the present invention also include administering a bispecific anti-CD20 / anti-CD3 antibody to a CD20+ B cell cancer individual.
[0050] In certain embodiments, the methods of the present invention include administering a therapeutically effective amount of a bispecific anti-CD20 / anti-CD3 antibody to a CD20+B cell cancer individual. In a specific embodiment, the B cell cancer is acute lymphocytic leukemia or chronic lymphocytic leukemia. In other embodiments, the B cell cancer is inert or aggressive. In certain embodiments, the individual does not respond to previous treatment or has relapsed after previous treatment (e.g., anti-CD20 inhibitors (such as rituximab) treatment). In certain embodiments, the methods of the present invention also include administering an anti-PD-1 antibody to a B cell cancer individual.
[0051] In certain embodiments, the methods of the present invention include administering an anti-PD-1 antibody in combination with a bispecific anti-CD20 / anti-CD3 antibody to an individual in need as a "first-line" treatment (e.g., initial treatment). In other embodiments, an anti-PD-1 antibody in combination with a bispecific anti-CD20 / anti-CD3 antibody is administered as a "second-line" treatment (e.g., after a previous treatment). For example, an anti-PD-1 antibody in combination with a bispecific anti-CD20 / anti-CD3 antibody is administered as a "second-line treatment" to an individual who has relapsed after a previous treatment, such as with chemotherapy or rituximab.
[0052] In certain embodiments, the methods of the present invention are used to treat patients with MRD-positive diseases. Minimal residual disease (MRD) refers to a small number of cancer cells still present in a patient during or after treatment, wherein the patient may or may not show symptoms or signs of the disease. If not eliminated, such residual cancer cells often lead to recurrence of the disease. The present invention includes methods for suppressing and / or eliminating residual cancer cells in a patient when testing MRD. MRD can be analyzed according to methods known in the art (e.g., MRD flow cytometry). According to this aspect of the invention, these methods include administering to the desired individual an anti-PD-1 antibody in combination with a bispecific anti-CD20 / anti-CD3 antibody.
[0053] According to certain embodiments, the methods of the invention comprise administering to an individual a therapeutically effective amount of each of an anti-PD-1 antibody and a bispecific anti-CD20 / anti-CD3 antibody in combination with a third therapeutic agent. The third therapeutic agent can be, for example, an agent selected from the following: radiotherapy, chemotherapy, surgery, cancer vaccines, PD-L1 inhibitors (e.g., anti-PD-L1 antibodies), LAG3 inhibitors (e.g., anti-LAG3 antibodies), CTLA-4 inhibitors, TIM3 inhibitors, BTLA inhibitors, TIGIT inhibitors, CD47 inhibitors, indoleamine-2,3-dioxygenase (IDO) inhibitors, vascular endothelial growth factor (VEGF) antagonists, Ang2 inhibitors, transforming growth factor β (TGFβ) inhibitors, epidermal growth factor receptor (EGFR) inhibitors, antibodies against tumor-specific antigens (e.g., CA9, CA125, melanoma-associated antigen 3 (MAGE3), carcinoembryonic antigen (CEA), vimentin, tumor-M2-PK, prostate-specific antigen (PSA), mucin-1, MART-1 and CA19-9), vaccines (e.g., Bacillus Calmette-Guérin, Calmette-Guerin), granulocyte-macrophage colony stimulating factor, cytotoxins, chemotherapeutic agents, IL-6R inhibitors, IL-4R inhibitors, IL-10 inhibitors, cytokines such as IL-2, IL-7, IL-21 and IL-15, anti-inflammatory drugs such as corticosteroids and non-steroidal anti-inflammatory drugs, and dietary supplements such as antioxidants. In certain embodiments, the antibodies can be administered in combination with therapies including chemotherapeutic agents, radiotherapy and surgery. As used herein, the phrase 'in combination with' means that the antibody and the third therapeutic agent are administered to an individual simultaneously, such as immediately before or immediately after their administration. In certain embodiments, the third therapeutic agent is administered as a co-formulation of the antibodies. In a related embodiment, the present invention includes a method comprising administering a therapeutically effective amount of an anti-PD-1 antibody in combination with a bispecific anti-CD20 / anti-CD3 antibody to an individual who is receiving a background anti-cancer treatment regimen. The background anti-cancer treatment regimen may include a process of administering, for example, a chemotherapeutic agent or radiation therapy. The anti-PD-1 antibody in combination with the bispecific anti-CD20 / anti-CD3 antibody may be added immediately adjacent to the background anti-cancer treatment regimen. In some embodiments, the antibody is added as part of a "background step-down" regimen, in which the background anti-cancer therapy is gradually (e.g., in a stepwise manner) withdrawn from the individual over time, while the antibody is administered to the individual at a constant dose, or at an increasing dose, or at a decreasing dose over time.
[0054] In certain embodiments, the methods of the present invention include administering to a desired individual a therapeutically effective amount of an anti-PD-1 antibody in combination with a therapeutically effective amount of a bispecific anti-CD20 / anti-CD3 antibody, wherein administration of the antibody results in an increase in tumor growth inhibition. In certain embodiments, tumor growth is inhibited by at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, or about 80%, as compared to an untreated individual or an individual administered either antibody as a monotherapy. In certain embodiments, administration of an anti-PD-1 antibody and / or a bispecific anti-CD20 / anti-CD3 antibody results in increased tumor regression, tumor shrinkage, and / or disappearance. In certain embodiments, administration of an anti-PD-1 antibody and / or a bispecific anti-CD20 / anti-CD3 antibody results in a delay in tumor growth and formation, for example, as compared to an untreated individual or an individual treated with either antibody as a monotherapy, tumor growth can be delayed by about 3 days, more than 3 days, about 7 days, more than 7 days, more than 15 days, more than 1 month, more than 3 months, more than 6 months, more than 1 year, more than 2 years, or more than 3 years. In certain embodiments, administration of an anti-PD-1 antibody in combination with a bispecific anti-CD20 / anti-CD3 antibody prevents tumor recurrence and / or increases the duration of survival of an individual, for example, an increase in survival duration of more than 15 days, more than 1 month, more than 3 months, more than 6 months, more than 12 months, more than 18 months, more than 24 months, more than 36 months, or more than 48 months compared to an untreated individual or an individual administered with either antibody as a monotherapy. In certain embodiments, administration of a combined antibody increases progression-free survival or overall survival. In certain embodiments, administration of an anti-PD-1 antibody in combination with a bispecific anti-CD20 / anti-CD3 antibody increases remission and duration of remission in an individual, for example, by more than 2%, more than 3%, more than 4%, more than 5%, more than 6%, more than 7%, more than 8%, more than 9%, more than 10%, more than 20%, more than 30%, more than 40%, or more than 50% relative to an untreated individual or an individual who has received either antibody as a monotherapy. In certain embodiments, administration of an anti-PD-1 antibody and / or a bispecific anti-CD20 / anti-CD3 antibody to an individual with B-cell cancer results in complete disappearance of all signs of tumor cells ("complete remission"). In certain embodiments, administration of an anti-PD-1 antibody and / or a bispecific anti-CD20 / anti-CD3 antibody to an individual with B-cell cancer results in a reduction of tumor cells or tumor size by at least 30% or more ("partial remission"). In certain embodiments, administration of an anti-PD-1 antibody and / or a bispecific anti-CD20 / anti-CD3 antibody to an individual with a B-cell cancer results in complete or partial disappearance of tumor cells / lesions, including new, measurable lesions.Tumor reduction can be measured by any method known in the art, for example, X-ray, positron emission tomography (PET), computed tomography (CT), magnetic resonance imaging (MRI), cytological analysis, histological analysis, or molecular genetic analysis.
[0055] In certain embodiments, the combination of antibodies administered is safe and well tolerated by patients, with no increase in adverse side effects [e.g., increased cytokine release ("cytokine storm") or increased T cell activation] compared to patients administered the bispecific antibody as a monotherapy.
[0056] Anti-PD-1 antibodies and antigen-binding fragments thereof
[0057] According to certain exemplary embodiments of the present invention, these methods include administering a therapeutically effective amount of an anti-PD-1 antibody or an antigen-binding fragment thereof. As used herein, the term "antibody" includes immunoglobulin molecules comprising four polypeptide chains (two heavy chains (H) and two light chains (L) interconnected by disulfide bonds) and multimers thereof (e.g., IgM). In common antibodies, each heavy chain comprises a heavy chain variable region (abbreviated herein as HCVR or V H ) and the heavy chain constant region. The heavy chain constant region contains three domains: C H 1. C H 2 and C H 3. Each light chain comprises a light chain variable domain (abbreviated herein as LCVR or V L ) and the light chain constant region. The light chain constant domain contains a domain (C L 1). V H Area and V L The V regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDRs), interspersed with regions that are more conserved, termed framework regions (FRs). H and V L Composed of three CDRs and four FRs arranged from amino terminus to carboxyl terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. In various embodiments of the invention, the FRs of the anti-IL-4R antibody (or antigen-binding portion thereof) may be identical to human germline sequences, or may be naturally or artificially modified. An amino acid consensus sequence may be defined based on side-by-side analysis of two or more CDRs.
[0058] As used herein, the term "antibody" also includes the antigen binding fragment of a complete antibody molecule. As used herein, the term "antigen binding portion" of an antibody, "antigen binding fragment" of an antibody, etc. include any naturally occurring, enzymatically available, synthetic or genetically modified polypeptides or glycoproteins that specifically bind to an antigen to form a complex. Any suitable standard technique such as proteolytic digestion or the recombinant genetic engineering technology involving operation and expression of DNA encoding antibody variable domains and optionally antibody constant domains can be used, for example, the antigen binding fragment of an antibody derived from a complete antibody molecule. Such DNA is known and / or easily obtained or can be synthesized from, for example, commercial sources, DNA libraries (including, for example, phage antibody libraries). The DNA can be sequenced and chemically or by using molecular biological techniques, for example, to arrange one or more variable domains and / or constant domains into a suitable layout, or to introduce codons, produce cysteine residues, modify, add or delete amino acids, etc.
[0059] Non-limiting examples of antigen-binding fragments include: (i) Fab fragments; (ii) F(ab')2 fragments; (iii) Fd fragments; (iv) Fv fragments; (v) single-chain Fv (scFv) molecules; (vi) dAb fragments; and (vii) minimal recognition units consisting of amino acid residues that mimic the hypervariable region of an antibody (e.g., independent complementarity determining regions (CDRs) such as CDR3 peptides) or constrained FR3-CDR3-FR4 peptides. As used herein, the expression "antigen-binding fragment" also encompasses other modified molecules such as domain-specific antibodies, single domain antibodies, domain-deleted antibodies, chimeric antibodies, CDR-grafted antibodies, diabodies, triabodies, tetrabodies, minibodies, nanobodies (e.g., monovalent nanobodies, bivalent nanobodies, etc.), small modular immunopharmaceuticals (SMIPs), and shark variable IgNAR domains.
[0060] The antigen-binding fragment of an antibody will generally contain at least one variable domain. The variable domain can be of any size or amino acid composition and will generally contain at least one CDR adjacent to or in frame with one or more framework sequences. L Domain-associated V H In the antigen-binding fragment of the structural domain, V H and V L The domains may be arranged relative to each other in any suitable arrangement. For example, the variable region may be a dimer and contain V H -V H 、V H -V L or V L -V L Alternatively, the antigen-binding fragment of the antibody may contain a monomeric V H or V LStructural domain.
[0061] In certain embodiments, the antigen-binding fragment of an antibody may contain at least one variable domain covalently linked to at least one constant domain. Non-limiting, exemplary arrangements of variable and constant domains that may be found within the antigen-binding fragment of an antibody of the invention include: (i) V H -C H 1; (ii) V H -C H 2; (iii) V H -C H 3; (iv) V H -C H 1-C H 2; (v) V H -C H 1-C H 2-C H 3; (vi) V H -C H 2-C H 3; (vii) V H -C L ; (viii) V L -C H 1; (ix) V L -C H 2; (x) V L -C H 3; (xi) V L -C H 1-C H 2; (xii) V L -C H 1-C H 2-C H 3; (xiii) V L -C H 2-C H 3; and (xiv) V L -C L In any arrangement of variable domains and constant domains, including any of the exemplary arrangements listed above, the variable domains and constant domains may be directly connected to each other or may be connected by a complete or partial hinge region or linker region. The hinge region may be composed of at least 2 (e.g., 5, 10, 15, 20, 40, 60 or more) amino acids that produce a flexible or semi-flexible connection between adjacent variable domains and / or constant domains in a single polypeptide molecule. In addition, the antigen-binding fragment of an antibody of the present invention may comprise any of the variable domains and constant domain arrangements listed above that are attached to each other and / or to one or more monomeric V H or V LThe domains are in non-covalent association (eg, via disulfide bonds) as homodimers or heterodimers (or other multimers).
[0062] As used herein, the term "antibody" also includes multispecific (e.g., bispecific) antibodies. A multispecific antibody or an antigen-binding fragment of an antibody will generally contain at least two different variable domains, each of which is capable of specifically binding to an independent antigen or to a different epitope on the same antigen. Conventional techniques available in the art can be used to transform any multispecific antibody form for use in the antibodies of the present invention or antigen-binding fragments of the antibodies of the present invention. For example, the present invention includes a method comprising the use of a bispecific antibody in which one arm of the immunoglobulin is specific for PD-1 or a fragment thereof, and the other arm of the immunoglobulin is specific for a second therapeutic target or is conjugated to a therapeutic moiety. Exemplary bispecific formats that can be used in the context of the present invention include, without limitation, bispecific formats based on scFv or diabodies, IgG-scFv fusions, dual variable domains (DVD)-Ig, Quadroma, knobs-in-holes, common light chain (e.g., common light chain with knobs-in-holes, etc.), CrossMab, CrossFab, (SEED) body, leucine zipper, Duobody, IgG1 / IgG2, dual functional Fab (DAF)-IgG and Mab 2 Bispecific formats (for a review of the aforementioned formats, see, e.g., Klein et al., 2012, mAbs 4:6, 1-11, and references cited therein). Bispecific antibodies can also be constructed using peptide / nucleic acid conjugation, for example, where unnatural amino acids with orthogonal chemical reactivity are used to generate site-specific antibody-oligonucleotide conjugates, which then self-assemble into multimeric complexes of defined composition, valency, and geometry. (See, e.g., Kazane, e.g., J. Am. Chem. Soc. [Epub: Dec. 4, 2012]).
[0063] The antibody used in the inventive method can be a human antibody. As used herein, the term "human antibody" is intended to include antibodies with variable regions and constant regions derived from human germline immunoglobulin sequences. However, the human antibody of the present invention may include, for example, amino acid residues not encoded by human germline immunoglobulin sequences in CDR and especially CDR3 (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutations in vivo). However, as used herein, the term "human antibody" is not intended to include antibodies in which the CDR sequences from the germline of another mammalian species (such as mice) have been transplanted to human framework sequences.
[0064] The antibody used in the method of the present invention can be a recombinant human antibody. As used herein, the term "recombinant human antibody" is intended to include all human antibodies prepared, expressed, produced or separated by recombinant means, such as antibodies expressed by recombinant expression vectors transfected into host cells (described further below), antibodies separated from recombinant human antibody combinatorial libraries (described further below), antibodies separated from transgenic animals (e.g., mice) relative to human immunoglobulin genes (see, for example, Taylor et al., (1992) Nucl. Acids Res. 20: 6287-6295) or antibodies prepared, expressed, produced or separated by any other means involving splicing of human immunoglobulin gene sequences to other DNA sequences. Such recombinant human antibodies have variable regions and constant regions derived from human germline immunoglobulin sequences. However, in certain embodiments, such recombinant human antibodies undergo in vitro mutagenesis (or, when using animals that are transgenic relative to human Ig sequences, undergo in vivo somatic mutagenesis) and therefore, although derived from human germline V H and V L Sequence and related thereto, the V H and V L The amino acid sequence of the region is a sequence that may not naturally exist within the human antibody germline repertoire in vivo.
[0065] According to certain embodiments, the antibody used in the method of the present invention specifically binds to PD-1. The term "specific binding" and the like means that the antibody or its antigen-binding fragment forms a complex with an antigen that is relatively stable under physiological conditions. Methods for determining whether an antibody specifically binds to an antigen are well known in the art and include, for example, equilibrium dialysis, surface plasmon resonance, and the like. For example, as used in the context of the present invention, antibodies that "specifically bind" to PD-1 include antibodies that are measured in a surface plasmon resonance assay, with a K of less than about 500 nM, less than about 300 nM, less than about 200 nM, less than about 100 nM, less than about 90 nM, less than about 80 nM, less than about 70 nM, less than about 60 nM, less than about 50 nM, less than about 40 nM, less than about 30 nM, less than about 20 nM, less than about 10 nM, less than about 5 nM, less than about 4 nM, less than about 3 nM, less than about 2 nM, less than about 1 nM, or less than about 0.5 nM. D Antibodies that bind to PD-1 or a portion thereof. However, an isolated antibody that specifically binds to human PD-1 may have cross-reactivity to other antigens (such as PD-1 molecules) from other (non-human) species.
[0066] According to certain exemplary embodiments of the present invention, the anti-PD-1 antibody or antigen-binding fragment thereof comprises a heavy chain variable region (HCVR), a light chain variable region (LCVR) and / or a complementarity determining region (CDR), which comprises any amino acid sequence of the anti-PD-1 antibody described in U.S. Patent Publication No. 20150203579. In certain exemplary embodiments, the anti-PD-1 antibody or antigen-binding fragment thereof that can be used in the methods of the present invention comprises a heavy chain complementarity determining region (HCDR) comprising a heavy chain variable region (HCVR) and a light chain complementarity determining region (LCDR) comprising a light chain variable region (LCVR), the heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 1, and the light chain variable region comprising the amino acid sequence of SEQ ID NO: 2. According to certain embodiments, the anti-PD-1 antibody or antigen-binding fragment thereof comprises three HCDRs (HCDR1, HCDR2, and HCDR3) and three LCDRs (LCDR1, LCDR2, and LCDR3), wherein HCDR1 comprises the amino acid sequence of SEQ ID NO: 3; HCDR2 comprises the amino acid sequence of SEQ ID NO: 4; HCDR3 comprises the amino acid sequence of SEQ ID NO: 5; LCDR1 comprises the amino acid sequence of SEQ ID NO: 6; LCDR2 comprises the amino acid sequence of SEQ ID NO: 7; and LCDR3 comprises the amino acid sequence of SEQ ID NO: 8. In yet other embodiments, the anti-PD-1 antibody or antigen-binding fragment thereof comprises a HCVR comprising SEQ ID NO: 1 and a LCVR comprising SEQ ID NO: 2. In certain embodiments, the methods of the present invention include the use of an anti-PD-1 antibody, wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 9. In some embodiments, the anti-PD-1 antibody comprises a light chain comprising the amino acid sequence of SEQ ID NO: 10. An exemplary antibody comprising a heavy chain comprising the amino acid sequence of SEQ ID NO: 9 and a light chain comprising the amino acid sequence of SEQ ID NO: 10 is a fully human anti-PD-1 antibody, referred to as REGN2810. According to certain exemplary embodiments, the methods of the present invention include the use of REGN2810 or a bioequivalent thereof. As used herein, the term "bioequivalent" refers to an anti-PD-1 antibody or PD-1-binding protein or fragment thereof that is a drug equivalent or drug alternative that does not show significant differences in absorption rate and / or extent from REGN2810 when administered in a single or multiple doses at the same molar dose under similar experimental conditions. In the context of the present invention, the term refers to an antigen binding protein that binds to PD-1, and the antigen binding protein does not have clinically significant differences from REGN2810 in terms of its safety, purity and / or potency.
[0067] Other anti-PD-1 antibodies that can be used in the methods of the present invention include, for example, the antibody referred to in the art and known as nivolumab (US 8008449), pembrolizumab (US 8354509), MEDI0608 (US 8609089), pidilizumab (US 8686119), or any anti-PD-1 antibody described in US Pat. Nos. 6808710, 7488802, 8168757, 8354509, 8779105, or 8900587.
[0068] The anti-PD-1 antibodies used in the methods of the present invention may have a pH-dependent binding profile. For example, the anti-PD-1 antibodies used in the methods of the present invention may show reduced binding to PD-1 at acidic pH compared to neutral pH. Alternatively, the anti-PD-1 antibodies of the present invention may show enhanced binding to their antigens at acidic pH compared to neutral pH. The expression "acidic pH" includes a pH value of less than about 6.2, for example, about 6.0, 5.95, 5.9, 5.85, 5.8, 5.75, 5.7, 5.65, 5.6, 5.55, 5.5, 5.45, 5.4, 5.35, 5.3, 5.25, 5.2, 5.15, 5.1, 5.05, 5.0 or less. As used herein, the expression "neutral pH" means a pH of about 7.0 to about 7.4. The expression "neutral pH" includes pH values of about 7.0, 7.05, 7.1, 7.15, 7.2, 7.25, 7.3, 7.35 and 7.4.
[0069] In some cases, the K of the antibody binding to PD-1 at acidic pH D The K value of the antibody binding to PD-1 at neutral pH D The term "reduced binding to PD-1 at acidic pH compared to neutral pH" is used to describe an antibody or antigen-binding fragment thereof that exhibits an acidic / neutral K of about 3.0 or greater. D ratio, then the antibody or antigen-binding fragment thereof can be referred to as "having reduced binding to PD-1 at acidic pH compared to neutral pH". In certain exemplary embodiments, the acidic / neutral K of an antibody or antigen-binding fragment of the invention is D The ratio may be about 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, 10.0, 10.5, 11.0, 11.5, 12.0, 12.5, 13.0, 13.5, 14.0, 14.5, 15.0, 20.0, 25.0, 30.0, 40.0, 50.0, 60.0, 70.0, 100.0 or more.
[0070] Can, for example, by reducing (or enhancing) binding to a specific antigen at an acidic pH compared to a neutral pH and screening an antibody population, obtain an antibody with a pH-dependent binding characteristic. In addition, modifying the antigen-binding domain at the amino acid level can produce an antibody with a pH-dependent characteristic. For example, by replacing one or more amino acids (e.g., inside a CDR) of an antibody with a histidine residue, an antigen-binding domain with reduced antigen binding at an acidic pH relative to a neutral pH can be obtained. As used herein, the expression "acidic pH" means a pH of 6.0 or less.
[0071] Bispecific anti-CD20 / anti-CD3 antibody
[0072] According to certain exemplary embodiments of the invention, these methods include administering a therapeutically effective amount of a bispecific antibody that specifically binds CD3 and CD20. Such antibodies may be referred to herein, for example, as "anti-CD20 / anti-CD3" or "anti-CD20xCD3" or "CD20xCD3" bispecific antibodies or other similar terms.
[0073] As used herein, the expression "bispecific antibody" refers to an immunoglobulin comprising at least a first antigen binding domain and a second antigen binding domain. In the context of the present invention, the first antigen binding domain specifically binds to a first antigen (e.g., CD20), and the second antigen binding domain specifically binds to a different second antigen (e.g., CD3). Each antigen binding domain of a bispecific antibody comprises a heavy chain variable domain (HCVR) and a light chain variable domain (LCVR) each comprising three CDRs. In the case of a bispecific antibody, the CDRs of the first antigen binding domain may be named with the prefix "A" and the CDRs of the second antigen binding domain may be named with the prefix "B". Therefore, the CDRs of the first antigen binding domain may be referred to herein as A-HCDR1, A-HCDR2, and A-HCDR3; and the CDRs of the second antigen binding domain may be referred to herein as B-HCDR1, B-HCDR2, and B-HCDR3.
[0074] The first antigen binding domain and the second antigen binding domain are each connected to an independent multimerization domain. As used herein, a "multimerization domain" is any macromolecule, protein, polypeptide, peptide or amino acid that has the ability to associate with a second multimerization domain having the same or similar structure or configuration. In the context of the present invention, the multimerization component is the Fc portion of an immunoglobulin (comprising C H 2-C H 3 domains), e.g., an Fc domain selected from isotypes IgG1, IgG2, IgG3, and IgG4, and IgG of any allotype within each isotype group.
[0075] The bispecific antibodies of the present invention generally comprise two multimerization domains, e.g., two Fc domains that are each independently a separate part of an antibody heavy chain. The first and second multimerization domains may belong to the same IgG isotype, e.g., IgG1 / IgG1, IgG2 / IgG2, IgG4 / IgG4. Alternatively, the first and second multimerization domains may belong to different IgG isotypes, e.g., IgG1 / IgG2, IgG1 / IgG4, IgG2 / IgG4, etc.
[0076] Any bispecific antibody format or technology can be used to produce the bispecific antigen-binding molecules of the present invention. For example, an antibody or fragment thereof having a first antigen-binding specificity can be functionally linked (e.g., by chemical coupling, genetic fusion, non-covalent binding or other means) to one or more other molecular entities, such as another antibody or antibody fragment having a second antigen-binding specificity, to produce a bispecific antigen-binding molecule. Exemplary bispecific formats that can be used in the context of the present invention include, but are not limited to, for example, bispecific formats based on scFv or diabodies, IgG-scFv fusions, dual variable domains (DVD)-Ig, quadromas (Quadroma), knobs and mortars, common light chains (e.g., common light chains with knobs and mortars, etc.), CrossMab, CrossFab, (SEED) bodies, leucine zippers, Duobody, IgG1 / IgG2, dual-function Fab (DAF)-IgG and Mab 2 Bispecific formats (for review of the aforementioned formats, see, eg, Klein et al., 2012, mAbs 4:6, 1-11, and references cited therein).
[0077] In the case of bispecific antibodies of the invention, the Fc domain may comprise one or more amino acid changes (e.g., insertions, deletions, or substitutions) compared to the wild-type, naturally occurring form of the Fc domain. For example, the invention includes bispecific antigen-binding molecules comprising one or more modifications in the Fc domain, wherein the modifications result in a modified Fc domain with an altered (e.g., enhanced or weakened) binding interaction between Fc and FcRn. In one embodiment, the bispecific antigen-binding molecule comprises a C H Zone 2 or C H A modification in region 3, wherein the modification increases the affinity of the Fc domain for FcRn under an acidic environment (e.g., in an endosome where the pH ranges from about 5.5 to about 6.0). Non-limiting examples of such Fc modifications are disclosed in U.S. Patent Publication No. 20150266966, which is incorporated herein in its entirety.
[0078] The present invention also includes a first C H3 domain and the second Ig C H A bispecific antibody with 3 domains, wherein the first and second Ig C H The first Ig C domains differ from each other by at least one amino acid, and wherein the at least one amino acid difference reduces binding of the bispecific antibody to protein A as compared to a bispecific antibody lacking the amino acid difference. H 3 domains bind protein A and the second Ig C H The 3 domain contains a mutation that reduces or eliminates protein A binding, such as the H95R modification (according to IMGT exon numbering; according to EU numbering, H435R). H 3 may also contain a Y96F modification (according to IMGT numbering; Y436F according to EU numbering). H Other modifications found within 3 include: D16E, L18M, N44S, K52N, V57M, and V82I in the case of IgG1 antibodies (by IMGT; D356E, L358M, N384S, K392N, V397M, and V422I by EU); N44S, K52N, and V82I in the case of IgG2 antibodies (by IMGT; N384S, K392N, and V422I by EU); and Q15R, N44S, K52N, V57M, R69K, E79Q, and V82I in the case of IgG4 antibodies (by IMGT; Q355R, N384S, K392N, V397M, R409K, E419Q, and V422I by EU).
[0079] In certain embodiments, the Fc domain can be chimeric, having Fc sequences derived from more than one immunoglobulin isotype. For example, a chimeric Fc domain can comprise Fc sequences derived from human IgG1, human IgG2, or human IgG4. H C derived from zone 2 H 2 sequence or a portion or all of a C derived from human IgG1, human IgG2 or human IgG4 H 3 sequence. The chimeric Fc domain may also contain a chimeric hinge region. For example, the chimeric hinge portion may comprise an "upper hinge" sequence derived from the hinge region of human IgG1, human IgG2, or human IgG4, combined with a "lower hinge" sequence derived from the hinge region of human IgG1, human IgG2, or human IgG4. Specific examples of chimeric Fc domains that may be included in any antigen-binding molecule described herein include from the N-terminus to the C-terminus: [IgG4 C H1]-[IgG4 upper hinge]-[IgG2 lower hinge]-[IgG4 CH2]-[IgG4 CH3]. Another example of a chimeric Fc domain that can be included in any antigen-binding molecule described herein includes from the N-terminus to the C-terminus: [IgG1 C H 1]-[IgG1 upper hinge]-[IgG2 lower hinge]-[IgG4 CH2]-[IgG1 CH3]. These and other examples of chimeric Fc domains that can be included in any antigen-binding molecule of the present invention are described in U.S. Patent Publication No. 20140243504, which is incorporated herein in its entirety. Chimeric Fc domains and variants thereof having these overall structural arrangements can have altered Fc receptor binding, which in turn affects Fc effector function.
[0080] According to certain exemplary embodiments of the present invention, the bispecific anti-CD20 / anti-CD3 antibody or antigen-binding fragment thereof comprises a heavy chain variable region (A-HCVR and B-HCVR), a light chain variable region (LCVR) and / or a complementarity determining region (CDR) comprising any one of the amino acid sequences of the bispecific anti-CD20 / anti-CD3 antibody described in U.S. Patent Publication No. 20150266966. In certain exemplary embodiments, the bispecific anti-CD20 / anti-CD3 antibodies or antigen-binding fragments thereof that can be used in the context of the methods of the invention comprise: (a) a first antigen-binding arm comprising heavy chain complementarity determining regions (A-HCDR1, A-HCDR2, and A-HCDR3) of a heavy chain variable region (A-HCVR) comprising the amino acid sequence of SEQ ID NO: 11 and a light chain complementarity determining region (LCDR) of a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 12; and (b) a second antigen-binding arm comprising heavy chain CDRs (B-HCDR1, B-HCDR2, and B-HCDR3) of a HCVR (B-HCVR) comprising the amino acid sequence of SEQ ID NO: 13 and light chain CDRs of a LCVR comprising the amino acid sequence of SEQ ID NO: 12. According to certain embodiments, A-HCDR1 comprises the amino acid sequence of SEQ ID NO: 14; A-HCDR2 comprises the amino acid sequence of SEQ ID NO: 15; A-HCDR3 comprises the amino acid sequence of SEQ ID NO: 16; LCDR1 comprises the amino acid sequence of SEQ ID NO: 17; LCDR2 comprises the amino acid sequence of SEQ ID NO: 18; LCDR3 comprises the amino acid sequence of SEQ ID NO: 19; B-HCDR1 comprises the amino acid sequence of SEQ ID NO: 20; B-HCDR2 comprises the amino acid sequence of SEQ ID NO: 21; and B-HCDR3 comprises the amino acid sequence of SEQ ID NO: 22. In yet other embodiments, the bispecific anti-CD20 / anti-CD3 antibody or antigen-binding fragment thereof comprises: (a) a first antigen-binding arm comprising a HCVR (A-HCVR) comprising SEQ ID NO: 11 and a LCVR comprising SEQ ID NO: 12; and (b) a second antigen-binding arm comprising a HCVR (B-HCVR) comprising SEQ ID NO: 13 and a LCVR comprising SEQ ID NO: 12.
[0081] Other bispecific anti-CD20 / anti-CD3 antibodies that can be used in the methods of the invention include, for example, any of the antibodies described in U.S. Patent Publication Nos. 20140088295 and 20150166661.
[0082] Combination therapy
[0083] According to certain embodiments, the method of the present invention includes administering an anti-CD20 / anti-CD3 bispecific antibody in combination with an anti-PD-1 antibody to an individual. In certain embodiments, the method of the present invention includes administering antibodies for additive or synergistic activity to treat cancer, preferably blood cancer, more preferably B cell cancer (e.g., non-Hodgkin's lymphoma or acute lymphoblastic leukemia). As used herein, the expression "in combination with" means that the anti-CD20 / anti-CD3 bispecific antibody is administered before, after, or simultaneously with the anti-PD-1 antibody. The term "in combination with" also includes sequentially or simultaneously administering an anti-PD-1 antibody and a bispecific anti-CD20 / anti-CD3 antibody. For example, when administered "before" the bispecific anti-CD20 / anti-CD3 antibody, the anti-PD-1 antibody can be administered more than 150 hours, about 150 hours, about 100 hours, about 72 hours, about 60 hours, about 48 hours, about 36 hours, about 24 hours, about 12 hours, about 10 hours, about 8 hours, about 6 hours, about 4 hours, about 2 hours, about 1 hour, about 30 minutes, about 15 minutes, or about 10 minutes before the administration of the bispecific anti-CD20 / anti-CD3 antibody. When administered "after" the bispecific anti-CD20 / anti-CD3 antibody, the anti-PD-1 antibody can be administered about 10 minutes, about 15 minutes, about 30 minutes, about 1 hour, about 2 hours, about 4 hours, about 6 hours, about 8 hours, about 10 hours, about 12 hours, about 24 hours, about 36 hours, about 48 hours, about 60 hours, about 72 hours, or more than 72 hours after the administration of the bispecific anti-CD20 / anti-CD3 antibody. Administration "concurrently" with the bispecific anti-CD20 / anti-CD3 antibody means that the anti-PD-1 antibody is administered to the individual in a separate dosage form within less than 5 minutes of (before, after, or simultaneously with) administration of the bispecific anti-CD20 / anti-CD3 antibody or as a single combined dosage form comprising the anti-PD-1 antibody and the bispecific anti-CD20 / anti-CD3 antibody.
[0084] In certain embodiments, the methods of the present invention include administering a third therapeutic agent, wherein the third therapeutic agent is an anticancer drug. As used herein, "anticancer drug" means any substance useful for treating cancer, including but not limited to cytotoxins and agents such as antimetabolites, alkylating agents, anthracyclines, antibiotics, antimitotic agents, procarbazine, hydroxyurea, asparaginase, corticosteroids, mytotane (O, P'-(DDD)), biologics (e.g., antibodies and interferons), and radioactive substances. As used herein, "cytotoxin or cytotoxic agent / drug" also refers to a chemotherapeutic agent and means any substance that damages cells. Examples include (paclitaxel), temozolamide, cytochalasin B, gramicidin D, ethidium bromide, emetine, cisplatin, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicine, doxorubicin, doxycycline, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol and puromycin and their analogs or homologs.
[0085] In certain embodiments, the methods of the present invention include administering a third therapeutic agent selected from radiation therapy, surgery, a cancer vaccine, a PD-L1 inhibitor (e.g., an anti-PD-L1 antibody), a LAG-3 inhibitor, a CTLA-4 inhibitor (e.g., ipilimumab), a TIM3 inhibitor, a BTLA inhibitor, a TIGIT inhibitor, a CD47 inhibitor, another T cell co-inhibitor or ligand antagonist (e.g., an antibody to CD-28, 2B4, LY108, LAIR1, ICOS, CD160, or VISTA), an indoleamine-2,3-dioxygenase (IDO) inhibitor, a vascular endothelial growth factor (VEGF antagonist [e.g., "VEGF-Trap" such as Aflibercept or such as US 7,087,411, or anti-VEGF antibodies or antigen-binding fragments thereof (e.g., bevacizumab or ranibizumab) or small molecule kinase inhibitors of VEGF receptors (e.g., sunitinib, sorafenib or pazopanib)], Ang2 inhibitors (e.g., nesvacumab), transforming growth factor β (TGFβ) inhibitors, epidermal growth factor receptor (EGFR) inhibitors (e.g., erlotinib, cetuximab), agonists against co-stimulatory receptors (e.g., agonists against glucocorticoid-induced TNFR-related proteins), agonists against tumor-specific antigens (e.g., CA9, CA125, melanoma), Antibodies to the cytokine receptor antagonist (R-1), cytokine receptor antagonist (R-1), cytokine receptor antagonist (R-2), cytokine receptor antagonist (R-3), cytokine receptor antagonist (R-4), cytokine receptor antagonist (R-5), cytokine receptor antagonist (R-6), cytokine receptor antagonist (R-7), cytokine receptor antagonist (R-8), cytokine receptor antagonist (R-9), cytokine receptor antagonist (R-10), cytokine receptor antagonist (R-2), cytokine receptor antagonist (R-11), cytokine receptor antagonist (R-12), cytokine receptor antagonist (R-13), cytokine receptor antagonist (R-14), cytokine receptor antagonist (R-15), cytokine receptor antagonist (R-16), cytokine receptor antagonist (R-17), cytokine receptor antagonist (R-18), cytokine receptor antagonist (R-21), cytokine receptor antagonist (R-19), cytokine receptor antagonist (R-22), cytokine receptor antagonist (R-23), cytokine receptor antagonist (R-24), cytokine receptor antagonist (R-25), cytokine receptor antagonist (R-27), cytokine receptor antagonist (R-3), cytokine receptor antagonist (R-19), cytokine receptor antagonist (R-28), cytokine receptor antagonist (R-3), cytokine receptor antagonist (R-3), cytokine receptor ant ADC and anti-DS6-DM4 ADC), chimeric antigen receptor T cells (e.g., CD19-targeted T cells), anti-inflammatory drugs (e.g., corticosteroids and nonsteroidal anti-inflammatory drugs), and dietary supplements such as antioxidants.
[0086] In certain embodiments, the method of the present invention includes administering an anti-PD-1 antibody and an anti-CD20 / anti-CD3 bispecific antibody in combination with radiotherapy to produce a long-lasting anti-tumor response and / or enhance the survival of cancer patients. In some embodiments, the method of the present invention includes administering radiotherapy to cancer patients before, simultaneously, or after administering anti-PD-1 antibodies and bispecific anti-CD20 / anti-CD3 antibodies. For example, after administering one or more doses of antibodies, radiotherapy can be administered to tumor lesions in one or more doses. In some embodiments, radiotherapy can be locally administered to tumor lesions to enhance the local immunogenicity of patient tumors (adjuvant radiotherapy) and / or after systemic administration of anti-PD-1 antibodies and / or bispecific anti-CD20 / anti-CD3 antibodies, killing tumor cells (ablative radiotherapy). In certain embodiments, antibodies can be administered in combination with radiotherapy and chemotherapeutic agents (e.g., temozolomide or cyclophosphamide) or VEGF antagonists (e.g., aflibercept).
[0087] Pharmaceutical compositions and kits
[0088] The present invention includes methods comprising administering to an individual an anti-PD-1 antibody in combination with a bispecific anti-CD20 / anti-CD3 antibody, wherein the antibodies are contained within a pharmaceutical composition alone or in combination (single one). The pharmaceutical compositions of the present invention can be formulated with suitable carriers, excipients, and other substances that provide suitable transfer, delivery, tolerance, etc. A variety of suitable formulations can be found in the formulary known to all pharmacists: Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, PA. These formulations include, for example, powders, pastes, ointments, mucilages, waxes, oils, lipids, (cationic or anionic) lipids containing vesicles (such as LIPOFECTIN TM ), DNA conjugates, anhydrous absorption pastes, oil-in-water and water-in-oil emulsions, carbowax emulsions (polyethylene glycols of various molecular weights), semisolid gels, and semisolid mixtures containing carbowax. See also Powell et al., "Compendium of excipients for parenteral formulations" PDA (1998) J Pharm Sci Technol 52: 238-311.
[0089] A variety of delivery systems are known and can be used to administer the pharmaceutical compositions of the invention, e.g., encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing mutant viruses, receptor-mediated endocytosis (e.g., see Wu et al., 1987, J. Biol. Chem. 262: 4429-4432). Methods of administration include, but are not limited to, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes. The composition can be administered by any convenient route, e.g., by infusion or bolus injection, by absorption through the epithelial or mucocutaneous layers (e.g., oral mucosa, rectal and intestinal mucosa, etc.), and can be administered with other biologically active substances.
[0090] The pharmaceutical composition of the present invention can be delivered subcutaneously or intravenously with a standard needle and syringe. In addition, relative to subcutaneous delivery, pen delivery devices are easily used to deliver the pharmaceutical composition of the present invention. Such pen delivery devices can be reusable or disposable. Reusable pen delivery devices generally utilize a replaceable column containing the pharmaceutical composition. Once the entire pharmaceutical composition in the column has been administered and the column is empty, the empty column can be easily discarded and replaced with a new column containing the pharmaceutical composition. The pen delivery device can then be reused. In a disposable pen delivery device, there is no replaceable column. Instead, the disposable pen delivery device is pre-filled with the pharmaceutical composition contained in the internal reservoir of the device. Once the reservoir is emptied of the pharmaceutical composition, the entire device is discarded.
[0091] In some cases, the pharmaceutical composition can be delivered in a controlled release system. In one embodiment, a pump can be used. In another embodiment, a polymer material can be used; see, Medical Applications of Controlled Release, Langer and Wise (eds.), 1974, CRC Pres., Boca Raton, Florida. In yet another embodiment, a controlled release system can be placed close to the target of the composition, so only a portion of the systemic dose is required (see, e.g., Goodson, 1984, cited in Medical Applications of Controlled Release, supra, Vol. 2, pp. 115-138). Other controlled release systems are discussed in the review of Langer, (1990) Science 249: 1527-1533.
[0092] Injectable products can include dosage forms for intravenous, subcutaneous, intradermal and intramuscular injections, instillations, etc. These injectable products can be prepared by known methods. For example, the antibody or its salt described above can be dissolved, suspended or emulsified in a conventional sterile aqueous medium or an oily medium for injection, and the injectable products can be prepared. As an injection water medium, for example, there is physiological saline, an isotonic solution containing glucose and other adjuvants, etc., which can be combined with suitable solubilizers such as ethanol (for example, ethanol), polyols (for example, propylene glycol, polyethylene glycol), nonionic surfactants [for example, polysorbate-80, HCO-50 (polyoxyethylene (50mol) adduct of hydrogenated castor oil)], etc. As an oily medium, sesame oil, soybean oil, etc., which can be used in combination with solubilizers such as benzyl benzoate, benzyl alcohol, etc., are used. The injection prepared in this way is preferably filled in a suitable ampoule.
[0093] Advantageously, the oral or parenteral pharmaceutical composition described above is formulated into a dosage form in a unit dose suitable for matching the dosage of the active ingredient. The types of dosage forms in a unit dose include, for example, tablets, pills, capsules, injections (ampoules), suppositories, etc.
[0094] Administration regimen
[0095] The present invention includes methods comprising administering an anti-PD-1 antibody to an individual at a dosing frequency of about four times a week, twice a week, once a week, once every two weeks, once every three weeks, once every four weeks, once every five weeks, once every six weeks, once every eight weeks, once every twelve weeks, or less, as long as a therapeutic response is achieved. In certain embodiments, the present invention includes methods comprising administering a bispecific anti-CD20 / anti-CD3 antibody to an individual at a dosing frequency of about four times a week, twice a week, once a week, once every two weeks, once every three weeks, once every four weeks, once every five weeks, once every six weeks, once every eight weeks, once every twelve weeks, or less, as long as a therapeutic response is achieved. In certain embodiments, these methods involve administering an anti-PD-1 antibody in combination with a bispecific anti-CD20 / anti-CD3 antibody at a dosing frequency of about four times a week, twice a week, once a week, once every two weeks, once every three weeks, once every four weeks, once every five weeks, once every six weeks, once every eight weeks, once every twelve weeks, or less, as long as a therapeutic response is achieved.
[0096] According to certain embodiments of the present invention, multiple doses of anti-PD-1 antibodies in combination with bispecific anti-CD20 / anti-CD3 antibodies can be administered to an individual within a limited time. According to this aspect of the present invention, these methods include sequentially administering to an individual one or more doses of anti-PD-1 antibodies in combination with one or more doses of bispecific anti-CD20 / anti-CD3 antibodies. As used herein, "sequential administration" means administering each dose of antibody to an individual at different time points, for example, at different days separated by a predetermined interval (e.g., hours, days, weeks, or months). The present invention includes such a method, which includes sequentially administering to a patient a single initial dose of an anti-PD-1 antibody, followed by one or more second doses of an anti-PD-1 antibody, and optionally followed by one or more third doses of an anti-PD-1 antibody. In certain embodiments, these methods also include sequentially administering to a patient a single initial dose of a bispecific anti-CD20 / anti-CD3 antibody, followed by one or more second doses of a bispecific antibody, and optionally followed by one or more third doses of a bispecific antibody.
[0097] According to certain embodiments of the present invention, multiple doses of anti-PD-1 antibodies and bispecific anti-CD20 / anti-CD3 antibodies can be administered to an individual over a defined time course. According to this aspect of the present invention, the methods include sequentially administering multiple doses of anti-PD-1 antibodies and bispecific anti-CD20 / anti-CD3 antibodies to an individual. As used herein, "sequential administration" means administering each dose of an anti-PD-1 antibody in combination with a bispecific antibody to an individual at different time points, for example, at different days separated by a predetermined interval (e.g., hours, days, weeks, or months).
[0098] The terms "initial dose", "second dose" and "third dose" refer to the time sequence of administration. Thus, the "initial dose" is the dose administered at the beginning of the treatment regimen (also referred to as the "baseline dose"); the "second dose" is the dose administered after the initial dose; and the "third dose" is the dose administered after the second dose. The initial, second and third doses can all contain the same amount of antibody (anti-PD-1 antibody or bispecific antibody). However, in certain embodiments, the amounts contained in the initial, second and / or third doses during treatment are different from each other (e.g., adjusted up or down as appropriate). In certain embodiments, one or more (e.g., 1, 2, 3, 4 or 5) doses are administered as a "loading agent" at the beginning of the treatment regimen, followed by subsequent doses (e.g., "maintenance doses") administered at a lower frequency. For example, an anti-PD-1 antibody can be administered to a B-cell cancer patient at a loading dose of about 1-3 mg / kg, followed by one or more maintenance doses of about 0.1 to about 20 mg / kg of the patient's body weight.
[0099] In an exemplary embodiment of the invention, each second and / or third dose is administered immediately after the preceding dose. 1 / 2 to 14 (e.g. 1 / 2, 1, 1 1 / 2,2,2 1 / 2,3,3 1 / 2,4,4 1 / 2,5,5 1 / 2,6,6 1 / 2,7,7 1 / 2,8,8 1 / 2,9,9 1 / 2, 10, 10 1 / 2, 11, 11 1 / 2, 12, 12 1 / 2, 13, 13 1 / 2, 14, 14 1 As used herein, the phrase "the immediately preceding dose" means the dose of anti-PD-1 antibody (and / or bispecific anti-CD20 / anti-CD3 antibody) administered to a patient immediately prior to the next dose in the series, administered without an intervening dose, in a series of multiple administrations.
[0100] According to this aspect of the invention, the methods may include administering any number of second and / or third doses of anti-PD-1 antibodies (and / or bispecific anti-CD20 / anti-CD3 antibodies) to the patient. For example, in certain embodiments, only a single second dose is administered to the patient. In other embodiments, two or more (e.g., 2, 3, 4, 5, 6, 7, 8, or more) second doses are administered to the patient. Similarly, in certain embodiments, only a single third dose is administered to the patient. In other embodiments, two or more (e.g., 2, 3, 4, 5, 6, 7, 8, or more) third doses are administered to the patient.
[0101] In embodiments involving multiple second doses, each second dose can be administered at the same frequency as other second doses. For example, each second dose can be administered to the patient 1 to 2 weeks after the dose immediately preceding it. Similarly, in embodiments involving multiple third doses, each third dose can be administered at the same frequency as other third doses. For example, each third dose can be administered to the patient 2 to 4 weeks after the dose immediately preceding it. Alternatively, the frequency at which the second and / or third dose is administered to the patient can vary during the treatment regimen. The frequency of administration can also be adjusted by a physician during treatment according to the needs of individual patients after clinical examination.
[0102] In certain embodiments, one or more doses of an anti-PD-1 antibody and / or a bispecific anti-CD20 / anti-CD3 antibody are administered at the beginning of a treatment regimen as an "induction dose" on a higher frequency (twice a week, once a week, or once within 2 weeks), followed by subsequent doses ("consolidation doses" or "maintenance doses") administered on a lower frequency (e.g., once within 4-12 weeks).
[0103] The present invention includes such a method, which comprises sequentially administering to a patient an anti-PD-1 antibody in combination with a bispecific anti-CD20 / anti-CD3 antibody to treat B cell cancer (e.g., non-Hodgkin's lymphoma, acute lymphoblastic leukemia). In some embodiments, the method of the present invention comprises administering one or more doses of an anti-PD-1 antibody, followed by one or more doses of a bispecific anti-CD20 / anti-CD3 antibody. In certain embodiments, the method of the present invention comprises administering a single dose of an anti-PD-1 antibody, followed by one or more doses of a bispecific anti-CD20 / anti-CD3 antibody. In some embodiments, one or more doses of an anti-PD-1 antibody of about 0.1 mg / kg to about 20 mg / kg, followed by one or more doses of a bispecific antibody of about 0.1 mg / kg to about 10 mg / kg, may be administered to inhibit tumor growth and / or prevent tumor recurrence in individuals with B cell cancer. In some embodiments, the anti-PD-1 antibody is administered in one or more doses, followed by one or more doses of the bispecific antibody, which results in increased anti-tumor efficacy (e.g., greater inhibition of tumor growth, prevention of tumor recurrence, as compared to untreated individuals, or individuals administered either antibody as a monotherapy). Alternative embodiments of the present invention relate to simultaneous administration of an anti-PD-1 antibody and a bispecific antibody administered at a similar or different frequency relative to the anti-PD-1 antibody in an independent dose. In some embodiments, the bispecific antibody is administered before, after, or simultaneously with the anti-PD-1 antibody. In certain embodiments, the bispecific antibody is administered as a single-dose formulation with an anti-PD-1 antibody.
[0104] dose
[0105] The amount of anti-PD-1 antibody and / or bispecific anti-CD20 / anti-CD3 antibody administered to an individual according to the methods of the present invention is generally a therapeutically effective amount. As used herein, the phrase "therapeutically effective amount" means the following amount of an antibody (anti-PD-1 antibody or bispecific anti-CD20 / anti-CD3 antibody), which results in one or more of the following: (a) a reduction in the severity or duration of symptoms of B-cell cancer compared to an untreated individual or an individual administered with either antibody as a monotherapy; (b) inhibition of tumor growth or increased tumor necrosis, tumor shrinkage, and / or tumor disappearance; (c) delayed tumor growth and development; (d) inhibition or delay or arrest of tumor metastasis; (e) prevention of tumor growth recurrence; (f) increased survival of individuals with B-cell cancer; and / or (g) a reduction in the use or need for conventional anti-cancer treatment (e.g., reduction or elimination of the use of chemotherapy or cytotoxic drugs).
[0106] In the case of an anti-PD-1 antibody, a therapeutically effective amount can be from about 0.05 mg to about 600 mg, such as about 0.05 mg, about 0.1 mg, about 1.0 mg, about 1.5 mg, about 2.0 mg, about 10 mg, about 20 mg, about 30 mg, about 40 mg, about 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg, about 110 mg, about 120 mg, about 130 mg, about 140 mg, about 150 mg, about 160 mg, about 170 mg, about 180 mg, about 190 mg, about 200 mg, about 210 mg, about 220 mg, about 230 mg, about 240 mg, about 250 mg, about 260 mg In some embodiments, the amount of anti-PD-1 antibody administered is about 250 mg, about 270 mg, about 280 mg, about 290 mg, about 300 mg, about 310 mg, about 320 mg, about 330 mg, about 340 mg, about 350 mg, about 360 mg, about 370 mg, about 380 mg, about 390 mg, about 400 mg, about 410 mg, about 420 mg, about 430 mg, about 440 mg, about 450 mg, about 460 mg, about 470 mg, about 480 mg, about 490 mg, about 500 mg, about 510 mg, about 520 mg, about 530 mg, about 540 mg, about 550 mg, about 560 mg, about 570 mg, about 580 mg, about 590 mg, or about 600 mg. In some embodiments, 250 mg of anti-PD-1 antibody is administered.
[0107] In the case of a bispecific anti-CD20 / anti-CD3 antibody, a therapeutically effective amount can be from about 10 micrograms (mcg) to about 8000 mcg, for example, about 10 mcg, about 20 mcg, about 50 mcg, about 70 mcg, about 100 mcg, about 120 mcg, about 150 mcg, about 200 mcg, about 250 mcg, about 300 mcg, about 350 mcg, about 400 mcg, about 450 mcg, about 500 mcg, about 550 mcg, about 600 mcg, about 700 mcg, about 800 mcg, about about 900mcg, about 1000mcg, about 1050mcg, about 1100mcg, about 1500mcg, about 1700mcg, about 2000mcg, about 2050mcg, about 2100mcg, about 2200mcg, about 2500mcg, about 2700mcg, about 2800mcg, about 2900mcg, about 3000mcg, about 4000mcg, about 5000mcg, about 6000mcg, about 7000mcg or about 8000mcg of a bispecific anti-CD20 / anti-CD3 antibody.
[0108] The amount of anti-PD-1 antibody or bispecific anti-CD20 / anti-CD3 antibody contained in each dose can be expressed in milligrams of antibody / kilogram of individual body weight (ie, mg / kg). In certain embodiments, the anti-PD-1 antibody or bispecific anti-CD20 / anti-CD3 antibody used in the methods of the present invention can be administered to an individual at a dose of about 0.0001 to about 100 mg / kg of individual body weight. For example, the anti-PD-1 antibody can be administered at a dose of about 0.1 mg / kg to about 20 mg / kg of patient body weight. The bispecific anti-CD20 / anti-CD3 antibody can be administered at a dose of about 0.1 mg / kg to about 10 mg / kg of patient body weight. Example
[0109] The following examples are provided to provide a complete disclosure and description of how to make and use the inventive method and composition for those skilled in the art, and are not intended to limit the scope of what the inventors regard as their invention. Efforts have been made to ensure accuracy in terms of the numbers used (e.g., amounts, temperatures, etc.), but some experimental errors and deviations should be considered. Unless otherwise indicated, parts are parts by weight, molecular weight is average molecular weight, temperature is degrees Celsius, and pressure is at or near atmospheric pressure.
[0110] Example 1: In vivo efficacy of anti-PD-1 antibody combined with anti-CD20xCD3 bispecific antibody against B16_CD20 tumors
[0111] In this example, the effect of PD-1 blockade combined with CD20-targeted immunotherapy was examined against B16_CD20 tumors established in CD20 and CD3 humanized mice using anti-mouse PD-1 and anti-human CD20xCD3 bispecific antibodies.
[0112] The exemplary bispecific anti-CD20 / anti-CD3 antibody used in the examples herein is "bsAb1" (also referred to as "antibody 1" disclosed in US20150266966), a fully human bispecific monoclonal antibody against CD20 and CD3, wherein the antibody comprises an anti-CD20 binding arm and an anti-CD3 binding arm, wherein the anti-CD20 binding arm comprises a first heavy chain variable region (A-HCVR) comprising an amino acid sequence of SEQ ID NO: 11 and a light chain variable region (LCVR) comprising an amino acid sequence of SEQ ID NO: 12; wherein the anti-CD3 binding arm comprises a second heavy chain variable region (B-HCVR) comprising an amino acid sequence of SEQ ID NO: 13 and an LCVR comprising an amino acid sequence of SEQ ID NO: 12. The bispecific antibody bsAb1 comprises a heavy chain CDR sequence and a light chain CDR sequence comprising SEQ ID NOs: 14-22.
[0113] use Using the technology, mice were engineered to be humanized for CD20 and CD3 (Valenzuela et al. 2003, Nat. Biotechnol. 21:652-659), which were then interbred to generate double humanized CD20CD3 mice (U.S. Patent Application No. 14 / 949,834, filed on November 23, 2015).
[0114] On day -7, mice were implanted subcutaneously with 2.5 x 10 5 On day 0, 35 mice with tumors between 25 and 115 mm 3The mice were randomly divided into five treatment groups. The mice were treated / treated with antibodies intraperitoneally twice a week as follows: Group 1: control (PBS); Group 2: isotype control (bivalent human antibody and rat IgG2a control-BE0089 for irrelevant antigens, from BioXCell); Group 3: anti-hCD20xCD3 (bsAb1) (4 mg / kg); Group 4: anti-mouse PD-1 antibody (10 mg / kg; RMPI-14_rIgG2a; BioXCell); and Group 5: anti-hCD20xCD3 (bsAb1) (4 mg / kg) + anti-mouse PD-1 antibody (10 mg / kg). All antibodies were administered intraperitoneally. In Group 5, mice were treated with antibodies simultaneously. During the duration of the experiment, tumor volume was monitored by caliper measurement twice a week, and tumor-free animals were monitored for tumor recurrence until 80 days.
[0115] Anti-PD-1 and anti-CD20xCD3 monotherapy delayed tumor growth in mice, with mice taking an average of 19 days to reach 500 mm 3 In contrast, mice treated with anti-PD-1 antibody plus anti-CD20xCD3 bispecific antibody took an average of 27 days to reach 500 mm tumor volume. 3 Tumor volume ( Figure 1 and Table 1).
[0116] Table 1: Tumor growth upon administration of anti-PD-1 antibody and bispecific anti-CD20 / anti-CD3 antibody
[0117] deal with <![CDATA[Achieve an average number of days of 500mm 3 > Tumor-free mice on day 30 PBS 15 0 / 7 Isotype Control 15 0 / 7 bsAb1 19 1 / 7 Anti-PD-1 (rIgG2a) 19 1 / 7 bsAb1+anti-PD-1 27 4 / 7
[0118] Monotherapy and combination treatment did not induce any changes in body weight and no macroscopic signs of toxicity were observed in any treatment group.
[0119] The above experiments were repeated twice and in both cases, the combination treatment resulted in a significant delay and inhibition of tumor growth compared to the control or monotherapy with anti-PD-1 antibody or bispecific anti-CD20 / CD3 antibody.
[0120] Example 2: In vivo efficacy of anti-PD-1 antibody and anti-CD20xCD3 bispecific antibody using a sequential dosing regimen
[0121] In this example, the anti-tumor effects of an anti-mouse PD-1 antibody in combination with an anti-human CD20xCD3 bispecific antibody were examined using a sequential dosing regimen.
[0122] use Technology was used to engineer double humanized CD20CD3 mice (Valenzuela et al. 2003, Nat. Biotechnol. 21: 652-659) (U.S. patent application No. 14 / 949,834, filed on November 23, 2015).
[0123] On day -7, mice were implanted subcutaneously with 2.5 x 10 5 On day 0, thirty-five mice with tumors between 30 and 65 mm 3 The mice were randomly divided into seven treatment groups ( Figure 2 ). Tumor growth was measured by caliper and body weight was recorded twice a week throughout the study. Mice were treated intraperitoneally with antibodies twice a week as follows: Group 1: control (PBS); Group 2: isotype control (bivalent human antibody against an irrelevant antigen and rat IgG2a control-BE0089, from BioXCell); Group 3: anti-mouse PD-1 antibody (10 mg / kg; RMPI-14_rIgG2a; BioXCell); Group 4: anti-hCD20xCD3 (bsAbl) (4 mg / kg); Group 5: anti-hCD20xCD3 (bsAbl) (4 mg / kg) + anti-mouse PD-1 antibody (10 mg / kg) administered simultaneously; Group 6: anti-mouse PD-1 antibody (10 mg / kg), followed by anti-hCD20xCD3 (bsAbl) (4 mg / kg); and Group 7: anti-hCD20xCD3 (bsAbl) (4 mg / kg), followed by anti-mouse PD-1 antibody (10 mg / kg). All antibodies were administered intraperitoneally using the sequential dosing schedule shown in Table 2.
[0124] Table 2: Sequential dosing regimen
[0125]
[0126] As compared with the single-arm control, simultaneous administration of bsAb1 and anti-mouse PD-1 antibody or anti-mPD-1 antibody followed by bsAb1 showed significant delay in tumor growth ( Figure 3 In the combination therapy, where bsAb1 was given from D0 and anti-PD-1 antibody was given from D7, there was no delay in tumor growth compared to the single-treatment groups studied. No differences in weight loss or non-tumor-related mortality were observed when the combination was administered.
[0127] Example 3: Clinical trials of anti-PD-1 antibodies and anti-CD20xCD3 antibodies in patients with B-cell malignancies
[0128] This study is an open-label, multicenter, dose-escalation study with multiple dose-escalation and expansion groups, designed to investigate the efficacy, safety, and tolerability of anti-PD-1 antibodies and anti-CD20 / anti-CD3 bispecific antibodies alone and in combination in adult patients with B-cell malignancies (including B-cell non-Hodgkin lymphoma, Hodgkin lymphoma, and acute lymphoblastic leukemia).
[0129] The exemplary anti-PD-1 antibody used in this example is REGN2810 (also known as H4H7798N as disclosed in US20150203579), a fully human monoclonal anti-PD-1 antibody comprising a heavy chain comprising the amino acid sequence of SEQ ID NO: 9 and a light chain comprising the amino acid sequence of SEQ ID NO: 10; a HCVR / LCVR amino acid sequence pair comprising SEQ ID NO: 1 / 2; and a heavy chain CDR sequence and a light chain CDR sequence comprising SEQ ID NO: 3-8.
[0130] An exemplary bispecific anti-CD20 / anti-CD3 antibody used in this example is bsAbl (described in Example 1).
[0131] The primary objectives of the studies were to evaluate the safety, tolerability, and dose-limiting toxicities (DLTs) of (i) single-agent REGN2810 in patients with lymphoma (B-cell non-Hodgkin lymphoma [B-NHL] and Hodgkin's lymphoma [HL]); (ii) single-agent bsAb1 in patients with acute lymphoblastic leukemia (ALL); (iii) the combination of bsAb1 and REGN2810 in patients with B-NHL; and (iv) the combination of bsAb1 and REGN2810 in patients with ALL.
[0132] The secondary objectives of the study are to: (i) determine the recommended dose of REGN2810 as a single agent in patients with lymphoma (B-NHL and HL); the recommended dose of bsAb1 as a single agent in patients with ALL; the recommended dose of bsAb1 and REGN2810 administered in combination in patients with B-NHL; and the recommended dose of bsAb1 and REGN2810 administered in combination in patients with ALL; (ii) characterize the pharmacokinetic (PK) profiles of bsAb1 and REGN2810 when administered as single agents and in combination; (iii) evaluate the immunogenicity of bsAb1 and REGN2810 when administered as single agents and in combination; and (iv) investigate the preliminary anti-tumor activity of bsAb1 and REGN2810 when administered as single agents in specific indications and in combination, as measured by overall response rate at 6 and 12 months, minimal residual disease (MRD) in patients with myeloid disease at baseline, duration of response, progression-free survival, median progression-free survival, and progression-free survival rate.
[0133] Additional objectives were to evaluate biomarkers that may be associated with mechanism of action, observe toxicity, and potential antitumor activity, including but not limited to: cytokine profiles; peripheral blood B-cell and T-cell subsets and immunophenotyping; gene expression changes in peripheral blood; and serum immunoglobulins.
[0134] Study Group
[0135] The target population includes patients with lymphoma (B-NHL and HL) and ALL for whom standard of care options do not exist. The various pathological subtypes eligible for the different trial groups are listed in Tables 3-5.
[0136] Table 3: Eligibility of Pathological Subtypes of Lymphoma Based on WHO Classification for Each Treatment Group: Dose Escalation of Single-Agent REGN2810 in B-NHL Cohort and HL Cohort
[0137]
[0138]
[0139] Table 4: Eligibility of Pathological Subtypes of Lymphoma Based on WHO Classification for Each Treatment Group: Single-Agent REGN2810 Expansion Cohort
[0140]
[0141] Table 5: Eligibility of Pathological Subtypes of Lymphoma Based on WHO Classification for Each Treatment Group: Dose Escalation and Expansion Cohorts for Combination of bsAb1 and REGN2810
[0142]
[0143]
[0144] Inclusion criteria for B-NHL treatment group and HL treatment group
[0145] Patients must meet the following criteria to be eligible for inclusion in this study: (1) Hematologic malignancies defined as follows: a. NHL: documented CD20+ B-cell malignancy with active disease resistant to or relapsed after most recent treatment for which standard of care options do not exist and anti-CD20 antibody therapy may not be appropriate: i. B-NHL according to WHO 2008 criteria (Campo 2011), b. Documented HL according to WHO 2008 criteria (Campo 2011), 2011), with active disease that was unresponsive to or relapsed after prior treatment for whom there was no standard of care option (REGN2810 monotherapy cohort only); (2) all patients had to have at least 1 bidimensionally measurable lesion (≥1.5 cm) as demonstrated by diagnostic imaging (CT, PET-CT, or MRI); (3) age ≥18 years; (4) Eastern Cooperative Oncology Group (ECOG) performance status ≤1; (5) life expectancy of at least 6 months; (6) adequate bone marrow function as demonstrated by: a. platelet count ≥75 x 10 9 / L b. Hemoglobin level ≥9g / dL c. ANC ≥1x 10 9 / L (Note: Patients with cell counts below the thresholds listed above may be considered for inclusion if, in the investigator's opinion, the cause is current bone marrow infiltration due to an underlying malignancy. In this case, the investigator must discuss eligibility with the sponsor and receive written approval for inclusion); (7) Adequate liver function: a. Total bilirubin ≤1.5x upper limit of normal (ULN) (if liver involvement, ≤3x ULN) b. Transaminase ≤2.5x ULN (if liver involvement, ≤5x ULN) c. Alkaline phosphatase ≤2.5x ULN (if liver involvement, ≤5x ULN) (Note: Patients with malignant tumors involving the liver, 3x ULN ≤ aspartate aminotransferase (AST) and / or alanine aminotransferase (ALT) ≤5x ULN and 1.5xULN ≤ total bilirubin ≤3x Patients with ULN. Note: Patients with Gilbert syndrome do not need to meet this requirement, provided that their total bilirubin has not changed from their baseline. Note: Patients may be considered for inclusion if, in the investigator's opinion, the abnormal laboratory results are attributable to an underlying malignancy. In this case, the investigator must discuss eligibility with the sponsor and receive written approval for inclusion); (8) Serum creatinine ≤1.5x ULN or calculated creatinine clearance according to Cockcroft-Gault ≥ 50 mL / min (Note: Patients who do not meet the creatinine clearance criteria according to Cockcroft-Gault may be considered for inclusion if the measured creatinine clearance (based on 24-hour urine or other reliable method) is ≥ 50 mL / min. Note: Patients may be considered for inclusion if, in the investigator's opinion, the abnormal laboratory results are attributed to a current underlying malignancy. In this case, the investigator must discuss eligibility with the sponsor and receive written approval for inclusion); (9) normal cardiac ejection fraction within the study unit's normal range based on pre-treatment MUGA or echocardiography within 4 weeks prior to inclusion; (10) willing to undergo mandatory pre-treatment tumor biopsy if, in the investigator's opinion, the patient has an accessible impairment that can be biopsied without significant risk to the patient; (11) willing and able to comply with clinic visits and study-related procedures; and (12) provide signed informed consent.
[0146] Exclusion criteria for B-NHL treatment group and HL treatment group
[0147] Patients who meet any of the following criteria will be excluded from this study: (1) primary central nervous system (CNS) lymphoma, or known or suspected CNS involvement by non-primary CNS NHL; (2) history of relevant CNS pathology or current relevant CNS pathology, such as: a. epilepsy, seizures, paresis, aphasia, stroke, severe brain injury, cerebellar disease, organic brain syndrome, psychosis, or b. evidence of inflammatory lesions and / or vasculitis on brain MRI during screening; (3) current or recent (within 2 years) evidence of overt autoimmune disease requiring treatment with systemic immunosuppressive therapeutic agents, which may indicate a risk of iAEs; (4) receipt of standard anti-lymphoma chemotherapy (non-biological) or radiotherapy less than 28 days before the first dose of study drug; (5) treatment with investigational non-biological drugs less than 28 days before the first dose of study drug; (6) treatment with alemtuzumab less than 12 weeks before the first dose of study drug; (7) treatment with rituximab, immunomodulatory drugs, or other investigational or commercial biologic drugs less than 28 days before the first dose of study drug. Examples of immunomodulatory drugs include blockers of CTLA-4, 4-1BB (CD137), LAG3, OX-40, therapeutic vaccines, or cytokine therapy; (8) Prior allogeneic stem cell transplantation; (9) Prior treatment with drugs that block the PD-1 / PD-L1 pathway, unless the patient demonstrates benefit (applicable only to patients treated with REGN2810 monotherapy) (Note: such patients should be discussed with the sponsor's medical monitor prior to enrollment); (10) Coexisting active malignancies for which the patient is receiving treatment; (11) Evidence of significant comorbidities or medical conditions that may interfere with study conduct or place the patient at significant risk, including but not limited to significant cardiovascular disease (e.g., New York Heart Association class III or IV heart disease, myocardial infarction within 6 months prior to screening, unstable arrhythmias, or unstable angina) and / or significant pulmonary disease (e.g., obstructive pulmonary disease and symptomatic bronchitis). (12) known active bacterial, viral, fungal, Mycobacterium tuberculosis, or other infections or any major infectious episode requiring hospitalization or intravenous anti-infective treatment within 14 days prior to the first administration of study drug; (13) human immunodeficiency virus (HIV) infection or active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection; (14) history of lung tissue inflammation within the last 5 years; (15) history of allergic reactions attributed to compounds with chemical or biological composition similar to the study drug; (16) history of hypersensitivity reactions to any compound in the tetracycline antibiotic group (a precautionary measure due to the possible presence of trace components in the study drug materials); (17) known hypersensitivity reactions to allopurinol and rasburicase; (18) pregnant or lactating women; and (19) sexually active fertile men or women who are unwilling to practice adequate contraception during the study and until 6 months after discontinuation of study drug.
[0148] Inclusion criteria for the acute lymphoblastic leukemia study group
[0149] Patients must meet the following criteria to be eligible for inclusion in this study: (1) Documented relapsed or refractory CD20+ (defined as CD20 expression on ≥20% of leukemic lymphoblasts by flow cytometry) B-lineage ALL after at least induction chemotherapy and 1 cycle of consolidation chemotherapy. a. Philadelphia chromosome-positive ALL patients are required to have failed or been intolerant to at least 1 tyrosine kinase inhibitor. Note: Patients with chronic myeloid leukemia (CML) blast crisis with a lymphoid phenotype are allowed if they meet inclusion criteria #1; (2) Age ≥18 years; (3) ECOG performance status ≤2; (4) Negative CNS disease as confirmed by lumbar puncture within 28 days prior to initiation of study drug (see Appendix 5); (5) Adequate bone marrow function as demonstrated by: a. Platelet count ≥10 x 10 9 / L b.Hb level ≥7g / dL c.Absolute phagocyte count ≥0.5x 10 9 / L (phagocytes: neutrophils, bands, and monocytes); (6) Adequate liver function: a. Total bilirubin ≤1.5x ULN (≤3x ULN if liver involvement) b. Transaminase ≤2.5x ULN (≤5x ULN if liver involvement) c. Alkaline phosphatase ≤2.5x ULN (≤5x ULN if liver involvement) (Note: Patients with Gilbert syndrome do not need to meet this requirement, provided that their total bilirubin has not changed from their baseline. Note: If, in the investigator's opinion, the abnormal laboratory results are attributed to an underlying malignancy, the patient may be considered for inclusion. In this case, the investigator must discuss eligibility with the sponsor and receive written approval for inclusion); (7) Serum creatinine ≤1.5x ULN or calculated creatinine clearance according to Cockcroft-Gault ≥ 50 mL / min (Note: Patients who do not meet the creatinine clearance criteria according to Cockcroft-Gault may be considered for inclusion if the measured creatinine clearance (based on 24-hour urine or other reliable method) is ≥ 50 mL / min. Note: Patients may be considered for inclusion if, in the investigator's opinion, the abnormal laboratory results are attributed to a current underlying malignancy. In this case, the investigator must discuss eligibility with the sponsor and receive written approval for inclusion); (8) no signs of acute or chronic graft-versus-host disease (GvHD) and no anti-GvHD medication within 14 days prior to initiation of study drug; (9) normal cardiac ejection fraction within the normal range of the study unit based on pre-treatment MUGA or echocardiography within 4 weeks prior to inclusion; (10) willing and able to comply with outpatient visits and study-related procedures; and (11) provide signed informed consent.
[0150] Exclusion criteria for acute lymphoblastic leukemia treatment group
[0151] Patients who meet any of the following criteria will be excluded from this study: (1) history of relevant CNS pathology or current relevant CNS pathology, such as: a. epilepsy, seizures, paresis, aphasia, stroke, severe brain injury, cerebellar disease, organic brain syndrome, psychosis, or b. evidence of inflammatory lesions and / or vasculitis on brain MRI during screening; (2) Burkitt's leukemia; (3) leukemia currently involving the testes; (4) current or recent (within 2 years) evidence of significant autoimmune disease (except GvHD) requiring treatment with systemic immunosuppressive therapeutic agents, which may indicate a risk of iAEs; (5) receipt of standard anti-leukemic chemotherapy (non-biological) or radiotherapy less than 14 days before the first dose of study drug; (6) treatment with investigational non-biological drugs less than 14 days before the first dose of study drug; (7) treatment with rituximab, immunomodulatory drugs, or other investigational or commercial biologic drugs less than 14 days before the first dose of study drug. (Examples of immunomodulatory drugs include blockade of CTLA-4, 4-1BB (CD137), LAG3, OX-40, therapeutic vaccines, or cytokine therapy); (8) treatment with alemtuzumab less than 12 weeks before the first dose of study drug; (9) previous allogeneic stem cell transplantation within 3 months of treatment; (10) coexisting active malignancy for which the patient is being treated; (11) evidence of significant coexisting diseases or medical conditions that may interfere with the conduct of the study or place the patient at significant risk, including but not limited to significant cardiovascular disease (e.g., New York Heart Association class III or IV heart disease, myocardial infarction within 6 months prior to screening, unstable arrhythmia, or unstable angina) and / or significant pulmonary disease (e.g., history of obstructive pulmonary disease and symptomatic bronchospasm); (12) first dose of Known active bacterial, viral, fungal, Mycobacterium tuberculosis, or other infections or any major infectious episodes requiring hospitalization or intravenous anti-infective treatment within 14 days prior to study drug use; (13) HIV infection or active HBV or HCV infection; (14) history of lung tissue inflammation within the past 5 years; (15) history of allergic reactions attributed to compounds with chemical or biological composition similar to the study drug; (16) history of hypersensitivity reactions to any compound in the tetracycline antibiotic group (a precautionary measure due to the possible presence of trace components in the study drug materials); (17) known hypersensitivity reactions to allopurinol and rasburicase; (18) pregnant or lactating women; and (19) sexually active fertile men or women who are unwilling to practice adequate contraception during the study and for up to 6 months after discontinuation of study drug.
[0152] Study Design
[0153] This is an open-label, multicenter, dose-escalation study with multiple dose-escalation and expansion groups. Patients were assigned to one of the following groups based on their diagnosis and according to the study stage at enrollment: single-agent REGN2810, single-agent bsAb1, or a combination of the two drugs.
[0154] Treatment groups and dose cohorts for patients with lymphoma (B-NHL and HL) are detailed in Figure 4 Assign patients to one of the following groups:
[0155] Single-agent REGN2810 in patients with lymphoma (B-NHL and HL)
[0156] · 2 dose escalation cohorts (1 mg / kg and 3 mg / kg)
[0157] 3 expansion cohorts: a) indolent B-NHL, b) aggressive B-NHL, and c) combination therapy in patients with HL B-NHL
[0158] Multiple dose escalation cohorts
[0159] 2 expanded cohorts: a) indolent B-NHL, and b) aggressive B-NHL
[0160] The monotherapy and combination therapy groups for ALL patients are described in detail in Figure 5 Assign patients to one of the following groups:
[0161] Single-agent bsAb1 groups in ALL patients
[0162] Multiple dose escalation cohorts
[0163] · 2 expansion cohorts: a) refractory / relapsed ALL, and b) minimal residual disease-positive (MRD+) ALL
[0164] Combination therapy in patients with ALL
[0165] Multiple dose escalation cohorts
[0166] · Two expansion cohorts: a) refractory / relapsed ALL and b) MRD-positive ALL. Combination therapy treatment will be initiated after submission of single-agent data and review by relevant health authorities.
[0167] Single-agent REGN2810 in patients with lymphoma (B-NHL and HL)
[0168] Figure 6The single-agent REGN2810 treatment regimen for patients with lymphoma is shown. Patients are administered REGN2810 IV every 2 weeks (Q2W) at the prescribed dose level (DL). Patients receive a minimum of 12 doses (24 weeks) and up to a maximum of 24 doses (48 weeks) of REGN2810. Patients who have a complete response, stable disease, or partial response with no change in tumor burden assessment across 3 consecutive tumor assessments after a minimum of 24 weeks of treatment and in consultation with the investigator and sponsor may also choose to discontinue treatment. Once treatment is completed (24 weeks or 48 weeks), there will be a 24-week (6-month) follow-up period.
[0169] Single-agent bsAb1 in ALL patients
[0170] Figure 7 Single-agent bsAb1 treatment regimens for ALL patients are shown. Patients were assigned to a DL consisting of an initial starting dose followed by subsequent higher doses provided the initial starting dose was tolerated (Table 6).
[0171] Table 6: Dose levels of bsAb1
[0172]
[0173] Intravenous bsAbl was administered weekly for 11 doses, followed by every 4 weeks (Q4W) treatment for an additional 6 doses, starting at week 13. After completing bsAbl treatment, patients were followed for an additional 6 months.
[0174] Combination therapy
[0175] There were 2 separate combination groups; one for B-NHL patients and another for ALL patients. Figure 8 Show combination therapy for patients with B-NHL and Fig. 9 Shown is a combination therapy regimen for patients with ALL.
[0176] Patients were administered REGN2810 IV Q2W at the prescribed DL (0.3 mg / kg, 1 mg / kg, or 3 mg / kg). Patients received a minimum of 12 doses (24 weeks) and up to a maximum of 24 doses (48 weeks) of REGN2810. Patients who achieved complete response, stable disease, or partial response with no change in tumor burden assessment for 3 consecutive tumor assessments after a minimum of 24 weeks of treatment and in consultation with the investigator and sponsor may also choose to stop treatment.
[0177] Patients will be assigned bsAbl DL consisting of an initial starting dose followed by subsequent higher doses provided the initial starting dose is tolerated (Table 6).IV bsAbl will be administered weekly for 11 doses followed by Q4W treatment starting in Week 13 for an additional 6 doses.
[0178] At study visits where both bsAbl and REGN2810 are administered, REGN2810 will be administered first. Patients will be followed for at least an additional 6 months after completing bsAbl treatment. The initiation of follow-up will depend on how long the patient has been treated with REGN2810 (24 weeks or 48 weeks).
[0179] Starting dose
[0180] Single-agent REGN2810 : In the absence of unexpected safety observations, the starting dose of REGN2810 in lymphoma patients was 1 mg / kg once every 2 weeks. Single-agent REGN2810 expansion in the setting of indolent B-NHL, aggressive B-NHL, and HL was determined in single-agent REGN2810 dose escalation cohorts in lymphoma patients (B-NHL and HL).
[0181] Single-agent bsAb1 : Starting DL of single-agent bsAb1 in ALL patients based on observed safety. The starting dose of the initial DL in ALL patients will be at least 10-fold lower than the starting dose of the DL with clear safety; however, the starting DL will not be lower than DL1. Single-agent bsAb1 expansion in refractory / relapsed ALL and MRD-positive ALL will be determined in the ALL dose escalation group.
[0182] Combination group - B-NHL patients : The dose plan for REGN2810 in combination with bsAb1 in B-NHL patients is 3 mg / kg Q2W, provided that there are no unexpected safety observations in the dose escalation of single-agent REGN2810 in the setting of B-cell malignancies. The starting DL of bsAb1 in combination with REGN2810 in B-NHL patients will be 1 DL lower than the starting DL with a clear safety profile and will not be lower than DL1.
[0183] Combination group-ALL patients : The dose plan for REGN2810 in ALL patients when co-administered with bsAb1 is 3 mg / kg Q2W, provided that there are no unexpected safety observations in the dose escalation of single-agent REGN2810 in the setting of B-cell malignancies. The starting DL for bsAb1 in ALL patients when co-administered with REGN2810 will be the DL that has a clear safety profile and has demonstrated minimal evidence of bioactivity within the single-agent bsAb1 dose escalation group in ALL patients in this study. Minimum bioactivity is defined as evidence of a 50% reduction in bone marrow blasts (partial response) at the bone marrow assessment performed at Week 5 in at least 1 of the 3 patients treated at the prescribed dose level.
[0184] Dose escalation
[0185] In all arms and all cohorts, the dose escalation rules will follow the traditional 3+3 dose escalation design, enrolling 3 to 6 patients per cohort.
[0186] The dose-limiting toxicity (DLT) observation period was defined as the first 28 days of treatment for all cohorts in all groups. Any of the following events occurring within the first 28 days of treatment (and determined by the investigator to be related to study treatment) were considered DLTs: ≥ Grade 2 uveitis, Grade 4 neutropenia, Grade 4 thrombocytopenia, and Grade 3 febrile neutropenia.
[0187] The maximum tolerated dose (MTD) was determined based on observed toxicities during the DLT observation period and was defined as the dose level (DL) immediately following the level at which dosing was discontinued due to DLT in 2 or more patients. If the dose escalation portion of a group was not discontinued due to DLT, the MTD was considered to have not been determined.
[0188] The optimal biological dose was also determined based on observed safety and tolerability, PK, PD, and preliminary antitumor activity.
[0189] The recommended dose for the expansion cohort is determined based on a review of the data used to determine the MTD and / or optimal biological dose.
[0190] The MTD, optimal biological dose, and recommended dose were determined independently for the single-agent group and each combination therapy group for the specific indication (NHL and ALL); up to 4 MTDs, the optimal biological dose and recommended dose could be determined. The MTD for any combination therapy group did not exceed the single-agent MTD DL, because DLTs occurred in 2 patients to this single-agent DL, and the determination of the MTD precluded further dose escalation.
[0191] Study Duration
[0192] The study treatment phase lasted from 6 to 12 months, depending on how individual patients responded to treatment. All patients were followed for 6 months.
[0193] Sample size: The exact number of patients to be enrolled depends on the occurrence of DLTs as defined in the study protocol and the number of DLs that will be opened. The sample size for dose escalation of single-agent REGN2810 in the lymphoma setting (B-NHL and HL) is up to 12 patients. The sample size for single-agent bsAb1 in ALL patients is up to 42 patients (depending on which DL the group starts with). The sample size for dose escalation of combination therapy in B-NHL patients is up to 42 patients (depending on which DL the group starts with). The sample size for dose escalation of combination therapy in ALL patients is up to 42 patients (depending on which DL the group starts with). Each expansion cohort will enroll 20 patients, for a total of 180 patients.
[0194] Study Treatment and Administration
[0195] BsAb1 is supplied as a liquid in a disposable sterile vial. Each vial contains 1mL of bsAb1 with a concentration of 2mg / mL that can be extracted. A pharmacist or other qualified individual is determined to prepare bsAb1 for administration at each research unit. The dose is received according to the dose level group distribution. The dose administered at each dose level is a nearly flat dose and is independent of the patient's weight or body surface area. Each dose of bsAb1 is administered by intravenous (IV) infusion over at least 60 minutes. According to the clinical judgment of the physician, the infusion time can be extended to up to 4 hours. In addition, the researcher can choose to divide this dose into 2 independent infusions over (preferably continuously) 2 days.
[0196] REGN2810 is supplied as a liquid in single-use sterile vials. Each vial contains enough volume to withdraw 10 mL of REGN2810 at a concentration of 25 mg / mL. REGN2810 will be administered as a 30-minute intravenous infusion. The dose for each patient will depend on individual body weight. The dose of REGN2810 should be adjusted for changes in body weight ≥10%. The dose will be adjusted for changes in body weight <10% at the discretion of the investigator.
[0197] At study visits where both bsAbl and REGN2810 were administered, REGN2810 was administered first.
[0198] Prior to administration of bsAb1 at doses of 300mcg or higher, premedication with dexamethasone is required at least 1 hour prior to infusion. At least 7.5mg of dexamethasone is recommended with the first initial dose of bsAb1 and the first administration of subsequent higher doses (dose escalation). If the patient tolerates the infusion without any signs or symptoms of infusion-related reactions or cytokine release syndrome (CRS), the investigator may reduce or eliminate the dexamethasone premedication dose administered prior to subsequent infusions as needed based on clinical judgment. Premedication with antihistamines and / or acetaminophen may also be considered. At doses less than 300mcg of bsAb1, empirical premedication with antihistamines, acetaminophen, and / or corticosteroids prior to study drug infusion is not recommended unless the patient has experienced an infusion-related reaction or Grade 2 or higher CRS with a previous infusion of bsAb1.
[0199] Patients with ALL who are at high risk for cytokine release syndrome (CRS) and / or TLS (defined by ≥50% lymphoblasts in the bone marrow; lactate dehydrogenase [LDH] ≥500 U / L; or extramedullary involvement) are recommended to receive premedication with dexamethasone. Premedication with dexamethasone should be 10 mg / m2 daily. 2 (QD) Minimum 3 days and maximum 5 days. Prior dexamethasone must be discontinued ≥72 hours prior to starting study medication.
[0200] At the time of relapse or progression, patients may be considered for retreatment. Retreatment may also be considered for patients with a suboptimal response. The choice of retreatment (increasing the dose of REGN2810, bsAb1, or the higher treatment the patient has already received) will depend on the initial treatment the patient received in the trial (e.g., single-agent bsAb1, REGN2810, or combination therapy) and which cohorts have clear safety at the time the patient is considered for retreatment. All retreatment decisions will be made after discussion between the treating investigator and the sponsor. At the time of relapse or progression, retreatment will be at the highest DL that has been determined to be safe and tolerable. Prior to retreatment, patients will be asked to re-sign informed consent and meet retreatment compliance criteria. For patients receiving monotherapy, if the treating physician believes that it is in the best interest of the patient to receive combination therapy at the time of relapse or progression, the patient may be switched to combination therapy at the combination dose level that has been determined to be safe and tolerable at the time the patient is considered for retreatment.
[0201] Study End Points
[0202] The primary endpoint was safety (specifically, adverse events [AEs], DLTs, safety laboratory data, and clinical performance). Secondary endpoints were: (i) PK of bsAb1 and REGN2810 alone and in combination; (ii) immunogenicity: anti-bsAb1 and / or anti-REGN2810 antibodies; (iii) antitumor activity: (a) overall response rate according to response criteria applicable to the indication; (b) duration of response and progression-free survival at 6 and 12 months; (c) minimal residual disease (MRD) assessment in patients with bone marrow involvement at baseline; and (iv) pharmacodynamic measures, including cytokine profiles, peripheral blood B and T cell subsets and immunophenotyping, analysis of PD-1 occupancy on circulating T cells, gene expression changes in peripheral blood, and serum immunoglobulins.
[0203] The percent change from baseline in target tumor size is also indicated and summarized.
[0204] Procedures and Assessment
[0205] Screening procedures to be performed include cardiac ejection fraction and brain MRI.
[0206] Safety procedures included medical history, physical examination, vital signs, electrocardiogram (ECG), coagulation profile, immune safety analysis (REGN2810-treated patients), B symptom assessment results and performance status assessment, clinical laboratory tests, AEs, and concomitant medications.
[0207] Procedures to be performed to evaluate tumor response include CT or MRI scans, 18F-fluorodeoxyglucose-positron emission tomography (FDG-PET) scans, bone marrow aspiration and biopsy (BMA / Bx), lumbar puncture, and lymph node and / or tumor biopsies.
[0208] NHL patients and HL patients were evaluated according to the Cheson criteria (Cheson et al. 2007, J. Clin. Oncol. 25(5):579-86). Fluorodeoxyglucose (FDG)-preferring patients were also evaluated according to the Lugano classification (Cheson et al. 2014, J. Clin. Oncol 32:3059-3067). ALL patients were evaluated according to the NCCN guidelines 2014.
[0209] Bone marrow samples were centrally assessed for the presence of MRD by polymerase chain reaction (PCR).MRD responses were determined in patients with ALL, follicular lymphoma, and marginal zone lymphoma according to Brüggemann et al. (Leukemia 2010, 24:521-35).
[0210] Blood samples were collected for evaluation of PK and anti-drug antibodies (ADA).
[0211] Biomarker samples are collected to monitor changes in cytokine production, serum levels of pro-inflammatory cytokines, and changes in lymphocyte subsets and activation status. In addition, these samples allow for tumor or somatic genetic analysis of changes that affect the clinical course of the underlying disease or modulate side effects of treatment.
[0212] Security
[0213] An adverse event (AE) is any unfavorable medical occurrence in a patient administered a study drug, which may or may not have a causal relationship with the study drug. Therefore, an AE is any unfavorable and unexpected sign (including abnormal laboratory results), symptom or disease that is temporally associated with the use of a study drug, regardless of whether it is deemed to be related to the study drug. AEs also include any deterioration of a pre-existing condition that is temporally associated with the use of a study drug (i.e., any clinically significant change in frequency and / or intensity). Progression of an underlying malignancy will not be identified as an AE if it is clearly consistent with the common progression pattern of the underlying cancer (including time course, organs involved, etc.). Progression of clinical symptoms may be reported as an AE if it cannot be determined that the symptoms are caused by a complete underlying malignancy or do not conform to the expected progression pattern of the disease being studied. A serious adverse event (SAE) is any adverse medical event that results in death, is life-threatening, requires hospitalization, causes persistent or significant disability, and / or is a major medical event at any dose.
[0214] Patients were monitored for vital signs, overall safety, cytokine release syndrome, B-cell depletion, central nervous system toxicity, and immune-mediated AEs.
[0215] Statistics Program
[0216] Dose escalation cohorts: The study design was based on a traditional 3+3 design with 3 to 6 patients per DL.
[0217] Expansion cohorts: Based on clinical considerations, the sample size of each expansion cohort was determined to be 20 patients to further explore the safety of the RP2D in the expansion cohort. The sample size of 20 patients also provides a preliminary assessment of tumor response.
[0218] All AEs reported in this study were coded using the currently available version of the Medical Dictionary for Regulatory Activities (MedDRA). Coding is to the lowest level term. The verbatim translation, preferred term (PT), and primary system organ class (SOC) are listed.
[0219] The summary of all treatment-emergent adverse events (TEAEs) by treatment group includes: (i) the number (n) and percentage (%) of patients with at least 1 TEAE by SOC and PT; (ii) TEAEs presented by SOC and PT according to severity; and (iii) TEAEs presented by SOC and PT according to relationship to treatment (related, unrelated). Deaths and other serious adverse events (SAEs) are listed and summarized by treatment group. Treatment-emergent adverse events that led to permanent discontinuation of treatment are listed and summarized by treatment group.
[0220] Efficacy analysis
[0221] Objective tumor responses according to disease-related criteria were summarized. Duration of response and progression-free survival at 6 and 12 months were listed according to Kaplan-Meier estimates, if applicable. Minimal residual disease status was listed and summarized. Progression-free survival was listed and summarized. The percent change from baseline in target tumor size was also summarized.
[0222] result
[0223] The antibodies alone and in combination are expected to be safe and well tolerated by patients. REGN2810 alone or in combination with bsAb1 is expected to inhibit tumor growth and / or promote tumor regression in patients with indolent or aggressive B-NHL or HL. ALL patients administered bsAb1 alone or in combination with REGN2810 are expected to show tumor growth inhibition and / or remission. The overall remission rate of the combination therapy is expected to be better as compared to either monotherapy.
[0224] The scope of the present invention is not limited by the specific embodiments described herein. In fact, various modifications of the present invention will be apparent to those skilled in the art due to the foregoing description and the accompanying drawings, in addition to these modifications described herein. Such modifications are intended to fall within the scope of the appended claims.
Claims
1. Use of (a) one or more doses of an antibody or antigen-binding fragment thereof that specifically binds to human programmed death 1 (PD-1) and (b) one or more doses of a bispecific antibody in the preparation of a medicament for treating or inhibiting tumor growth in a patient with a B-cell cancer, wherein the bispecific antibody comprises a first antigen-binding arm that specifically binds to human CD20 and a second antigen-binding arm that specifically binds to human CD3, wherein: The anti-PD-1 antibody or antigen-binding fragment thereof comprises three heavy chain complementarity determining regions (HCDR1, HCDR2, and HCDR3) of a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 1, and three light chain complementarity determining regions (LCDR1, LCDR2, and LCDR3) of a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 2; The first antigen-binding arm of the bispecific antibody comprises three heavy chain complementarity determining regions (CDRs) (A-HCDR1, A-HCDR2, and A-HCDR3) of a heavy chain variable region (A-HCVR) comprising the amino acid sequence of SEQ ID NO: 11 and three light chain CDRs (LCDR1, LCDR2, and LCDR3) of a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 12; The second antigen-binding arm of the bispecific antibody comprises three heavy chain CDRs (B-HCDR1, B-HCDR2, and B-HCDR3) of a heavy chain variable region (B-HCVR) comprising the amino acid sequence of SEQ ID NO: 13 and three light chain CDRs (LCDR1, LCDR2, and LCDR3) of a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 12; wherein tumor growth is inhibited by at least 50% compared to subjects administered either antibody as a monotherapy.
2. The use according to claim 1, wherein one or more doses of the anti-PD-1 antibody or antigen-binding fragment thereof comprises a dose of 0.05-600 mg.
3. The use according to claim 1, wherein each dose of the anti-PD-1 antibody or antigen-binding fragment thereof comprises 0.1-20 mg / kg body weight of the subject.
4. The use according to claim 3, wherein each dose of the anti-PD-1 antibody or antigen-binding fragment thereof comprises 0.3, 1, 3 or 10 mg / kg body weight of the subject.
5. The use according to claim 1, wherein one or more doses of the bispecific antibody comprises 10-8000 μg.
6. The use according to claim 5, wherein one or more doses of the bispecific antibody comprises 30, 100, 300, 1000 or 2000 μg.
7. The use according to claim 1, wherein each dose of the bispecific antibody comprises 0.1-10 mg / kg body weight of the subject.
8. The use according to claim 1, wherein the anti-PD-1 antibody or antigen-binding fragment thereof and the bispecific antibody are each in a form suitable for intravenous, subcutaneous or intraperitoneal administration.
9. The use according to claim 1, wherein the anti-PD-1 antibody or antigen-binding fragment thereof comprises a HCDR1 comprising the amino acid sequence of SEQ ID NO: 3; a HCDR2 comprising the amino acid sequence of SEQ ID NO: 4; a HCDR3 comprising the amino acid sequence of SEQ ID NO: 5; LCDR1 comprises the amino acid sequence of SEQ ID NO: 6; LCDR2 comprises the amino acid sequence of SEQ ID NO: 7; and LCDR3 comprises the amino acid sequence of SEQ ID NO:
8.
10. The use according to claim 1, wherein the anti-PD-1 antibody or antigen-binding fragment thereof has a HCVR comprising the amino acid sequence of SEQ ID NO: 1 and a LCVR comprising the amino acid sequence of SEQ ID NO:
2.
11. The use according to claim 1, wherein the anti-PD-1 antibody has a heavy chain comprising the amino acid sequence of SEQ ID NO: 9 and a light chain comprising the amino acid sequence of SEQ ID NO:
10.
12. The use according to claim 1, wherein the first antigen-binding arm of the bispecific antibody has an A-HCDR1 comprising the amino acid sequence of SEQ ID NO: 14; an A-HCDR2 comprising the amino acid sequence of SEQ ID NO: 15; an A-HCDR3 comprising the amino acid sequence of SEQ ID NO: 16; a LCDR1 comprising the amino acid sequence of SEQ ID NO: 17; a LCDR2 comprising the amino acid sequence of SEQ ID NO: 18; and a LCDR3 comprising the amino acid sequence of SEQ ID NO:
19.
13. The use according to claim 1, wherein the first antigen-binding arm of the bispecific antibody has an A-HCVR comprising the amino acid sequence of SEQ ID NO: 11 and a LCVR comprising the amino acid sequence of SEQ ID NO:
12.
14. The use according to claim 1, wherein the second antigen-binding arm of the bispecific antibody comprises a B-HCDR1 comprising the amino acid sequence of SEQ ID NO:20; a B-HCDR2 comprising the amino acid sequence of SEQ ID NO:21; a B-HCDR3 comprising the amino acid sequence of SEQ ID NO:22; a LCDR1 comprising the amino acid sequence of SEQ ID NO:17; LCDR2 comprising the amino acid sequence of SEQ ID NO:18; and LCDR3 comprising the amino acid sequence of SEQ ID NO:
19.
15. The use of claim 1, wherein the second antigen-binding arm of the bispecific antibody comprises a B-HCVR comprising the amino acid sequence of SEQ ID NO: 13, and a LCVR comprising the amino acid sequence of SEQ ID NO:
12.
16. The method according to any one of claims 1 to 15, wherein the B cell cancer comprises Hodgkin's lymphoma, non-Hodgkin's lymphoma, follicular lymphoma, small lymphocytic lymphoma, lymphoplasmacytoid lymphoma, marginal zone lymphoma, mantle cell lymphoma, diffuse large B cell lymphoma, B cell lymphoma, lymphomatoid granuloma, Burkitt's lymphoma, acute lymphocytic leukemia, hairy cell leukemia or B cell chronic lymphocytic leukemia.
17. The use according to any one of claims 1 to 15, wherein the anti-PD-1 antibody or antigen-binding fragment thereof and the bispecific antibody are administered in combination with a third therapeutic agent or a third therapy, wherein the third therapeutic agent or the third therapy is selected from radiation, surgery, a chemotherapeutic agent, a cancer vaccine, a PD-L1 inhibitor, a LAG-3 inhibitor, a CTLA-4 inhibitor, a TIM3 inhibitor, a BTLA inhibitor, a TIGIT inhibitor, a CD47 inhibitor, an indoleamine-2,3-dioxygenase (IDO) inhibitor, a vascular endothelial growth factor (VEGF) antagonist, an angiopoietin-2 (Ang2) inhibitor, a transforming growth factor β (TGFβ) inhibitor, an epidermal growth factor receptor (EGFR) inhibitor, an antibody against a tumor-specific antigen, a Bacillus Calmette-Guerin vaccine, a granulocyte-macrophage colony stimulating factor, a cytotoxin, an interleukin 6 receptor inhibitor, an interleukin 4 receptor (IL-4R) inhibitor, an IL-10 inhibitor, IL-2, IL-7, IL-21, IL-15, an antibody-drug conjugate, an anti-inflammatory drug, and a dietary supplement.
18. The use of any one of claims 1 to 15, wherein the anti-PD-1 antibody or antigen-binding fragment thereof is administered simultaneously with or after the bispecific antibody.
19. The use of any one of claims 1 to 15, wherein the anti-PD-1 antibody or antigen-binding fragment thereof is administered before the bispecific antibody.
20. The use of claim 19, wherein the anti-PD-1 antibody or antigen-binding fragment thereof is administered 1 week before the bispecific antibody.
21. The use according to any one of claims 1 to 15, wherein each dose of the anti-PD-1 antibody or antigen-binding fragment thereof is formulated for administration 0.5 to 12 weeks after the immediately preceding dose.
22. The use according to any one of claims 1 to 15, wherein each dose of the bispecific antibody is formulated for administration 0.5 to 12 weeks after the immediately preceding dose.
23. The use according to claim 23, wherein each dose of the anti-PD-1 antibody or antigen-binding fragment thereof is formulated for administration once every two weeks, and each dose of the bispecific antibody is formulated for administration once a week.
24. The use according to any one of claims 1 to 15, wherein each dose of the bispecific antibody is formulated for administration in 2 to 5 divided doses over a dosing period.
25. The use according to any one of claims 1 to 15, wherein the subject is resistant or inadequately responsive to previous treatment, or has relapsed after previous treatment.
26. The use according to any one of claims 1 to 15, wherein the treatment produces a therapeutic effect selected from the group consisting of delayed tumor growth, reduced tumor cell number, tumor regression, increased survival rate, partial response and complete response.
27. A drug delivery system for treating or inhibiting tumor growth in a subject with B-cell cancer, comprising: (a) a pharmaceutical composition comprising an antibody or an antigen-binding fragment thereof that specifically binds to human programmed death 1 (PD-1); and (b) a pharmaceutical composition comprising a bispecific antibody comprising a first antigen-binding arm that specifically binds to human CD20 and a second antigen-binding arm that specifically binds to human CD3, wherein: The anti-PD-1 antibody or antigen-binding fragment thereof comprises three heavy chain complementarity determining regions (CDRs) (HCDR1, HCDR2, and HCDR3) of a heavy chain variable region (HCVR), the heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 1, and three light chain CDRs (LCDR1, LCDR2, and LCDR3) of a light chain variable region (LCVR), the light chain variable region comprising the amino acid sequence of SEQ ID NO: 2; The first antigen-binding arm of the bispecific antibody comprises three heavy chain complementarity determining regions (CDRs) (A-HCDR1, A-HCDR2 and A-HCDR3) of a heavy chain variable region (A-HCVR) comprising the amino acid sequence of SEQ ID NO: 11 and three light chain CDRs (LCDR1, LCDR2 and LCDR3) of a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO:
12. And The second antigen-binding arm of the bispecific antibody comprises three heavy chain CDRs (B-HCDR1, B-HCDR2 and B-HCDR3) of a heavy chain variable region (B-HCVR) comprising the amino acid sequence of SEQ ID NO: 13, and three light chain CDRs (LCDR1, LCDR2 and LCDR3) of a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO:
12.
28. The drug delivery system of claim 27, wherein the anti-PD-1 antibody or antigen-binding fragment comprises a HCDR1 comprising the amino acid sequence of SEQ ID NO: 3; a HCDR2 comprising the amino acid sequence of SEQ ID NO: 4; a HCDR3 comprising the amino acid sequence of SEQ ID NO: 5; a LCDR1 comprising the amino acid sequence of SEQ ID NO: 6; a LCDR2 comprising the amino acid sequence of SEQ ID NO: 7; and a LCDR3 comprising the amino acid sequence of SEQ ID NO:
8.
29. The drug delivery system of claim 27, wherein the anti-PD-1 antibody or antigen-binding fragment comprises a HCVR comprising the amino acid sequence of SEQ ID NO: 1 and a LCVR comprising the amino acid sequence of SEQ ID NO:
2. 30 . The drug delivery system of claim 27 , wherein the anti-PD-1 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 9 and a light chain comprising the amino acid sequence of SEQ ID NO:
10.
31. The drug delivery system of claim 27, wherein the first antigen-binding arm of the bispecific antibody comprises an A-HCDR1 comprising the amino acid sequence of SEQ ID NO: 14; an A-HCDR2 comprising the amino acid sequence of SEQ ID NO: 15; an A-HCDR3 comprising the amino acid sequence of SEQ ID NO: 16; an LCDR1 comprising the amino acid sequence of SEQ ID NO: 17; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 18; and an LCDR3 comprising the amino acid sequence of SEQ ID NO:
19.
32. The drug delivery system of claim 27, wherein the first antigen-binding arm of the bispecific antibody comprises an A-HCVR comprising the amino acid sequence of SEQ ID NO:11 and a LCVR comprising the amino acid sequence of SEQ ID NO:
12.
33. A drug delivery system according to claim 27, wherein the second antigen-binding arm of the bispecific antibody comprises a B-HCDR1 comprising the amino acid sequence of SEQ ID NO:20; a B-HCDR2 comprising the amino acid sequence of SEQ ID NO:21; a B-HCDR3 comprising the amino acid sequence of SEQ ID NO:22; a LCDR1 comprising the amino acid sequence of SEQ ID NO:17; a LCDR2 comprising the amino acid sequence of SEQ ID NO:18; and a LCDR3 comprising the amino acid sequence of SEQ ID NO:
19.
34. The drug delivery system of claim 27, wherein the second antigen-binding arm of the bispecific antibody comprises a B-HCVR comprising the amino acid sequence of SEQ ID NO: 13 and a LCVR comprising the amino acid sequence of SEQ ID NO:
12.
35. The drug delivery system according to any one of claims 27 to 34, wherein the pharmaceutical composition comprising the anti-PD-1 antibody or antigen-binding fragment is separate from the pharmaceutical composition comprising the bispecific antibody.
36. The drug delivery system according to any one of claims 27 to 34, wherein the pharmaceutical composition comprising the anti-PD-1 antibody or antigen-binding fragment and the pharmaceutical composition comprising the bispecific antibody are combined into a single composition.
37. A drug delivery system according to any one of claims 27 to 34, wherein the amount of the bispecific antibody is 10 – 8000μg.
38. The drug delivery system according to any one of claims 27 to 34, wherein the amount of the bispecific antibody is 30, 100, 300, 1000 or 2000 μg.
39. The drug delivery system according to any one of claims 27 to 34, wherein the amount of the anti-PD-1 antibody or antigen-binding fragment is 0.05 – 600 mg.
40. A drug delivery system according to any one of claims 27-34, further comprising a third therapeutic agent selected from the group consisting of a chemotherapeutic agent, a cancer vaccine, a PD-L1 inhibitor, a LAG-3 inhibitor, a CTLA-4 inhibitor, a TIM3 inhibitor, a BTLA inhibitor, a TIGIT inhibitor, a CD47 inhibitor, an indoleamine-2,3-dioxygenase (IDO) inhibitor, a vascular endothelial growth factor (VEGF) antagonist, an angiopoietin-2 (Ang2) inhibitor, a transforming growth factor β (TGFβ) inhibitor, an epidermal growth factor receptor (EGFR) inhibitor, an antibody to a tumor-specific antigen, a Bacillus Calmette-Guérin, a granulocyte-macrophage colony stimulating factor, a cytotoxin, an interleukin 6 receptor (IL-6R) inhibitor, an interleukin 4 receptor (IL-4R) inhibitor, an IL-10 inhibitor, IL-2, IL-7, IL-21, IL-15, an antibody-drug conjugate, an anti-inflammatory drug, and a dietary supplement.
Citation Information
Patent Citations
Anti-CD3 antibodies, bispecific antigen-binding molecules that bind CD3 and CD20, and uses thereof
US20140088295A1
Antibodies comprising chimeric constant domains
US20140243504A1
Anti-CD3 antibodies and methods of use
US20150166661A1
Human Antibodies to PD-1
US20150203579A1
Methods and Antibody Compositions for Tumor Treatment
US20150266966A1
